




2021

April 25-30 / 25-30 avril


ANNUAL CONFERENCE
CONFÉRENCE ANNUELLE
AMMI Canada - CACMID



Where Canada's Experts in Clinical Microbiology
and Infectious Diseases Will Meet VIRTUALLY!



FINAL PROGRAM
PROGRAMME FINAL



WELCOME



On behalf of the Association of Medical Microbiology and Infectious Disease Canada and the Canadian Association for Clinical Microbiology and Infectious Diseases we would like to welcome you to the 17th annual conjoint meeting on the prevention, diagnosis, and treatment of infectious diseases. We are excited to be offering the event in a fully virtual format this year! From interactive scientific sessions to posters and an exhibit hall, this will be an excellent opportunity to learn and connect in an engaging online experience.

The Central and Scientific Planning Committees have put in long hours to produce an exceptional virtual program for attendees this year. There will be on-demand poster sessions and live oral presentations to showcase the research done by our students, residents, fellows, and colleagues, with awards for the best student abstracts presented at the conference. The state-of-the-art clinical lectures will cover up-to-date information on COVID-19 vaccines and immunity, the use of bacteriophages as antimicrobial therapies, zoonoses, and how artificial intelligence can be used to detect and control epidemics. The plenaries will focus on COVID-19, clinical controversies in infectious diseases and diagnostic microbiology, as well as hot topics in infection control, diagnostic microbiology, and both adult and paediatric infectious diseases. The Scientific Planning Committee

has also co-developed integrated symposia and workshops for delegates to attend. Lastly, excellent Trainees' Day interactive sessions are planned with ample opportunity for networking.

We would like to acknowledge the generous and continued support from our industry partners, sponsors, and exhibitors, which has allowed us to preserve our high-quality meeting. We encourage you to virtually walk through the exhibit hall, expand your network, and see what's new and exciting.

COVID-19 has put our professions at the forefront, and we are excited to bring together Canada's experts in this unique setting to not only highlight excellent COVID-19 research, but also other hot topics in clinical microbiology and infectious diseases.



AMMI Canada and CACMID are proud of the ongoing collaboration leading to this high-quality annual meeting. On behalf of the Central and Scientific Planning Committees, we look forward to seeing you online and providing you with not only an educational event, but also opportunities for you to have fun, network, and socialize with your colleagues.

Sarah Forgie

President, AMMI Canada

Tanis Dingle

President, CACMID



BIENVENUE

Au nom de l'Association pour la microbiologie médicale et l'infectiologie Canada et de l'Association canadienne de microbiologie clinique et des maladies infectieuses, nous vous souhaitons la bienvenue à la 17^e conférence annuelle conjointe sur la prévention, le diagnostic et le traitement des maladies infectieuses. Nous sommes heureux de tenir l'événement sous forme virtuelle cette année. À partir de séances scientifiques interactives jusqu'aux présentations par affiches en passant par la salle d'exposition, ce sera une excellente occasion de s'instruire et d'établir des liens dans une expérience en ligne engageante.

Les comités de planification générale et scientifique ont consacré de longues heures à la mise au point d'un programme exceptionnel. Il y aura diverses présentations par affiches et orales d'études effectuées par nos étudiants, résidents, boursiers et collègues, ainsi que la remise de prix pour les meilleurs résumés d'étudiants présentés à la conférence. Les exposés cliniques de pointe donneront des renseignements à jour sur les vaccins contre la COVID-19 et l'immunité, l'utilisation de bactériophages comme traitements antimicrobiens, les zoonoses, et comment l'intelligence artificielle peut servir à détecter et contrôler les épidémies. Les séances plénières porteront sur la COVID-19, les controverses cliniques dans les maladies infectieuses et la microbiologie diagnostique, ainsi que sur des sujets chauds dans le contrôle de l'infection, la microbiologie diagnostique et les maladies infectieuses chez les adultes et les enfants. Le Comité scientifique a

également co-élaboré des symposiums et ateliers intégrés pour les participants. Enfin, les excellentes séances interactives de la Journée des stagiaires constitueront d'excellentes occasions de réseautage.

Nous aimerions souligner le soutien généreux et continu de nos partenaires du secteur, de nos commanditaires et de nos exposants qui nous a permis de continuer à offrir cette conférence de grand calibre. Nous vous encourageons à visiter le salon des exposants, à élargir votre réseau et à découvrir ce qu'il y a de nouveau et d'intéressant.

La COVID-19 a mis nos professions à l'avant-garde et nous sommes heureux d'apporter des experts canadiens à cet événement unique non seulement pour mettre en évidence l'excellente recherche sur la COVID-19 mais aussi d'autres sujets chauds en microbiologie clinique et maladies infectieuses.

L'AMMI Canada et la CACMID sont fières de cette collaboration continue qui conduit à cette conférence de grande qualité. Au nom des comités de planification générale et scientifique, nous vous recevrons avec plaisir en ligne pour vous offrir non seulement un événement éducatif, mais de nombreuses possibilités de vous distraire, de réseauter et de socialiser avec vos collègues.

Sarah Forgie

Présidente, AMMI Canada

Tanis Dingle

Présidente, CACMID

COLLABORATING SOCIETIES



ASSOCIATION DES
MICROBIOLOGISTES DU
QUÉBEC




Canadian Association for
HIV Research
L'association canadienne de
recherche sur le VIH



Canadian Association for Immunization
Research, Evaluation and Education
Association Canadienne pour la recherche,
l'évaluation et l'éducation en immunisation



Canadian Foundation
for Infectious Diseases
Fondation canadienne
des maladies infectieuses



Canadian Society of
Hospital Pharmacists
Société canadienne des
pharmaciens d'hôpitaux



Canadian Society for Medical Laboratory Science
Société canadienne de science de laboratoire médical



Critical Care-Infectious
Diseases Network (CCIDN)



MANAGING INFECTIONS
PROMOTING SCIENCE



Infectious Diseases Society of America



Infection Prevention
and Control Canada



PAN AMERICAN
SOCIETY FOR
CLINICAL VIROLOGY



The Society for Healthcare
Epidemiology of America

CONTENTS

Welcome	2
Bienvenue	3
How to Use the Virtual Platform	4
Collaborating Societies	5
Are You a Member?	6

COMMITTEES, AND COUNCILS

AMMI Canada Council	7
CACMID Board	7
Central Planning Committee (CPC)	7
Scientific Planning Committee (SPC)	8
Sponsorship Committee	8
Abstract Review Committee	8

Accreditation

CanMEDS	9
---------	---

PROGRAM

Sunday, April 25	10
Monday, April 26	11
Tuesday, April 27	12
Wednesday, April 28	16
Thursday, April 29	18
Friday, April 30	19

Poster and Oral Awards

Save the date!	20
Speaker Biographies	21
E-Posters	22
Student E-Posters	28
Author Index	38
Conflict of Interest Declarations	44
Industry co-developed presentations	50
	53

UNACCREDITED PRESENTATIONS

Unaccredited Learning Activities	55
Exhibit Hall	60
Sponsors	61
General Information	61


HOW TO USE THE VIRTUAL PLATFORM





The 2021 AMMI Canada – CACMID Annual Conference looks different this year. We will be meeting virtually on the vFairs platform rather than in person.

Tips to help you get started and to ensure you have the best possible experience:

- Chrome, Firefox and Safari are the best browsers for video streaming the vFairs platform. **The platform does not respond well to Explorer**
- Downloading the most current version of Zoom will make the virtual experience more optimal
- Register: <https://ammi-cacmid2021.secure-registration.com/en/n7mb3v/event>



- Once you are registered, visit www.ammicanadacacmid2021.vfairs.com and login using the email address you registered with
- Once you are logged in, you will be brought into the 2021 annual conference lobby. From the lobby you have access to and are able to experience all the annual conference has to offer:
 - 3 auditoriums that will host the live and on demand (recorded) dynamic program,
 - 2 poster halls,
 - An interactive Exhibit Hall that allows for 1:1 video interaction with industry partners,
 - Networking lounges so you can catch up with friends and colleagues and,
 - Gamification for those with a little competitive nature in them.
- If you experience technical difficulties or have any questions, stop by the Information Desk in the lobby or email ammicanadacacmid@getvfairs.io or meetings@ammi.ca.



OBJECTIVES




The AMMI Canada – CACMID Annual Conference provides an interactive venue where experts in the fields of diagnostic microbiology, antimicrobial stewardship, infectious diseases, infection prevention and control, and public health meet. The conference attracts attendees from across Canada and internationally. As in previous years, the 2021 conference will provide updates on a variety of topics to a diverse audience of clinicians, microbiologists, laboratory technologists, public health professionals, infection prevention and control practitioners, students and residents. The one difference this year is that the full conference will be virtual given COVID-19.

In addition to the pre-meeting Trainees' Day, the program will offer plenary sessions, state of the art clinical lectures, integrated symposia,

short oral presentations, poster presentations and workshops. The Interactive Clinical Vignettes and the Incubator will be on hiatus in 2021 and will return in 2022. The 2021 meeting will be a chance for attendees to showcase their research as well as get up to speed with the latest in the areas of microbiology, infection control, adult and paediatric infectious diseases and related subjects. Dynamic expert speakers will be invited from across North America to ensure another exciting meeting.

In addition to the scientific component, the meeting will provide ample opportunity for attendees to network, exchange ideas, and reconnect with colleagues all within the comfort of your own home or office!



ARE YOU A MEMBER?

To join AMMI Canada please contact:

Terence Wuerz, MD, MSc, FRCPC
 Secretary, AMMI Canada
 c/o AMMI Canada Secretariat

192 Bank Street
 Ottawa, ON K2P 1W8

Toll-free: 1 (866) 467-1215
 Tel.: (613) 260-3233 ext. 103
 Fax: (613) 260-3235
 Email: membership@ammi.ca

For more information on AMMI Canada visit:
www.ammi.ca


To join CACMID please contact:

Ramzi Fattouh, PhD, FCCM
 Secretary, CACMID
 c/o Laboratory Medicine

St. Michael's Hospital
 30 Bond St., CC Rm 2-040
 Toronto, ON M5B 1W8

Email: info@cacmid.ca

For more information on CACMID visit:
www.cacmid.ca





AMMI Canada Council

President

Sarah Forgie, *Edmonton, AB*

President Elect

Deborah Yamamura, *Hamilton, ON*

Past President

Todd Hatchette, *Halifax, NS*

Treasurer

Andrew Simor, *Toronto, ON*

Secretary

Terence Wuerz, *Winnipeg, MB*

MM – Section Chair

Philippe Lagacé-Wiens, *Winnipeg, MB*

ID – Section Chair

Shariq Haider, *Hamilton, ON*

Members of Council

Isabelle Chiu, *Edmonton, AB*

Susy Hota, *Toronto, ON*

Yves Longtin, *Montréal, QC*

LeeAnne Luft, *Kelowna, BC*

Kelly MacDonald, *Winnipeg, MB*

Karina Top, *Halifax, NS*



CACMID Board

President

Tanis Dingle, *Edmonton, AB*

Vice President

Agatha Jassem, *Vancouver, BC*

Past President/Treasurer

Carmen Charlton, *Edmonton, AB*

Secretary

Ramzi Fattouh, *Toronto, ON*

Meeting Secretary/Councillor

Chris Lowe, *Vancouver, BC*

Scientific Planning Committee Co-Chair

Rob Kozak, *Toronto, ON*

Webmaster

Vanessa Tran, *Toronto, ON*

Councillor

Danielle Brabant-Kirwan, *Sudbury, ON*

Councillor

Esther Nagai, *Toronto, ON*

Councillor


Samir Patel, *Toronto, ON*

Councillor

Valentina Russell, *Winnipeg, MB*

Councillor

Prameet Sheth, *Kingston, ON*



Central Planning Committee (CPC)

Co-Chairs

Tanis Dingle
 Sarah Forgie

Scientific Planning Committee Co-Chairs

Robert Kozak
 Susan Poutanen
 Christine Turenne

Co-Treasurers

Carmen L. Charlton
 Andrew Simor

Sponsorship Committee

Co-Chairs

Jeff Fuller
 Shariq Haider


Abstract Co-Chairs

Christian Lavallée
 Christopher Lowe

Committee Members

Todd Hatchette
 Agatha Jassem

Scientific Planning Committee (SPC)



Co-Chairs

Robert Kozak
 Susan Poutanen
 Christine Turenne

Committee Members

Danielle Brabant-Kirwan
 Marthe Charles
 William Connors
 Melanie Di Quinzio
 Ramzi Fattouh
 Catherine Hogan
 Agatha Jassem
 Jennie Johnstone
 Farhan Khan

Philippe Lagacé-Wiens
 Christian Lavallée
 Christopher Lowe
 Kathy Malejczyk
 Esther Nagai
 Samir Patel
 David Patrick
 Glenn Patriquin
 Peter Pieroni
 Earl Rubin
 Valentina Russell
 Joanne Salmon
 Yoko Schreiber
 Prameet M. Sheth
 Vanessa Tran



Sponsorship Committee




Co-Chairs

Jeff Fuller
 Shariq Haider

Committee Members

Dwight Ferris
 Donald Vinh
 Titus Wong
 Deborah Yamamura



Abstract Review Committee


Co-Chairs

Christian Lavallée
 Christopher Lowe

Committee Members

Andrée-Anne Boisvert
 Danielle Brabant-Kirwan
 Julie Carson
 Vikas Chaubey
 Jeannette Comeau
 William Connors
 Peter Daley
 Meghan Dey
 Tanis Dingle
 Steven J. Drews
 Eric Eckbo
 Chelsey Ellis
 Ramzi Fattouh
 Jeff Fuller

Simon Grandjean-Lapierre
 Daniel B. Gregson
 David Harris
 Catherine Hogan
 B. Lynn Johnston
 Imane Jroundi
 Robert Kozak
 Jérôme Laflamme
 Clayton MacDonald
 Nancy Matic
 Vanessa Meier-Stephenson
 Muhammad Morshed
 Esther Nagai
 Conar O'Neil
 Peter Pieroni
 Prameet Sheth
 Christine Turenne
 Bing Wang
 Deborah Yamamura



ACCREDITATION



For specialists certified with the Royal College of Physicians and Surgeons of Canada (RCPSC): The AMMI Canada - CACMID Annual Conference is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. **You may claim a maximum of 20.75 hours.**


A. Mainport – Transfer of Hours

The Royal College of Physicians and Surgeons of Canada allows for attendance data of Section 1, Group Learning Activities to be transferred directly into participants' MAINPORT Transfer of Hours. Please indicate your RCPSC ID Number when registering.

B. For specialists certified with the American Medical Association (AMA): Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College

MOC credits to AMA PRA Category 1 Credits. Information on the process to convert Royal College MOC credits to AMA credits can be found at www.ama-assn.org/go/internationalcme. Please indicate your AMA ID Number when registering.

C. For Fellows and Specialists of the Canadian College of Microbiologists and Diplomats of the American Board of Medical Microbiology: The Canada College of Microbiologists (CCM) accredits the AMMI Canada – CACMID Annual Conference for CE credits. Certificates of continuing education activity are available through the CCM for documentation of attendance and maintenance of certification. A one-hour educational activity is equivalent to one CE credit. Program evaluation forms and record of CE activity can be obtained and returned, once completed, by email to the FCCM co-chair (hadam@shared-healthmb.ca) following the conference.



The AMMI Canada Education Committee Chair, Dr. Joanne Salmon, is responsible for ensuring that the AMMI Canada - CACMID Annual Conference is compliant with the Royal College National Standard for Support of Accredited CPD Activities.

CANMEDS

CanMEDS is a framework that identifies and describes the abilities physicians require to effectively meet the health care needs of the people they serve. These abilities are grouped thematically under seven roles. A competent physician seamlessly integrates the competencies of all seven CanMEDS Roles. CanMEDS Roles have been identified for each Plenary and State of the Art (START) Clinical Lecture using the following symbols:

- Collaborator 
- Communicator 
- Health Advocate 
- Leader 
- Medical Expert 
- Professional 
- Scholar 

(2021). Royal College of Physicians and Surgeons of Canada. CanMEDS Framework



PROGRAM

(all times indicated in Canadian Eastern time zone)

Sunday, April 25

On Demand Poster Viewing

On Demand Exhibit Hall

12:00 – 16:30 Trainees' Day

Auditorium: Main Auditorium

Moderator: Farhan Khan (Halifax, NS)

12:00 – 12:10 Welcome, Introductions and Overview

12:10 – 12:40 It's a Game of Grantsmanship, and Your Ship Just Came In

CM CL LE

SC PR

Speaker: Robert Kozak (Toronto, ON)

By the end of this session, participants should be able to:

- Understand the current grant landscape and how to leverage your skills when applying
- Learn my process for preparing for and writing a grant
- Appreciate the top 3 things I've learned from my grant successes and failures

12:40 – 13:10 Interactive Break Out Sessions

13:15 – 13:45 Navigating the Real World to Paradise Island!

CM CL LE PR

Speaker: Yoko Schreiber (Sioux Lookout, ON)

By the end of this session, participants should be able to:

- Recognize the many possible work applications and opportunities
- Explore strategies to identify and land your ideal job (including CVs and interviews)
- Acquire some personal tips for creating balance

13:45 – 14:15 Interactive Break Out Sessions

14:15 – 14:25 Health Break

14:25 – 14:55 You can do this! Prepping for Exams in ID, Med Micro, and Clin Micro

CL ME LE

SC PR

Speaker: Glenn Patriquin (Halifax, NS)

By the end of this session, participants should be able to:

- Describe the formats of the final examinations in Infectious Diseases, Medical Microbiology, and Clinical Microbiology
- Identify strategies and resources for exam preparation
- Begin developing a study plan in preparation for writing your exam

14:55 – 15:25 Interactive Break Out Sessions

15:30 – 15:40 Wrap Up and Closing Remarks

15:40 – 16:30 Trainees' Day Networking Lounge

Following Trainees' Day, you are invited to join the Trainees' Day Networking Lounge, to meet, mingle and catch up virtually with fellow trainees', speakers and members of the AMMI Canada and CACMID boards.

PROGRAM

(all times indicated in Canadian Eastern time zone)

Monday, April 26

On Demand Poster Viewing
On Demand Exhibit Hall

10:15 - 11:15 The Influenza Vaccine (R)Evolution
 HA ME SC

Auditorium: Co-Developed Presentations

Moderator: Philippe Lagacé-Wiens
 (Winnipeg, MB)

Speaker: Matthew Miller (Hamilton, ON)

By the end of the session the participants will be able to:

- Outline the main factors that impact annual influenza vaccine effectiveness

- Identify limitations in the use of randomized controlled trials to compare seasonal influenza vaccine efficacy
- Appreciate the need for real-world data related to influenza vaccines

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Seqirus and was planned to achieve scientific integrity, objectivity and balance.

11:15 - 11:30 Break

11:30 - 14:00 Plenary: COVID-19 - What We Know, What We Don't Know

Auditorium: Main Auditorium

Moderators: Robert Kozak (Toronto, ON)
 Susan Poutanen (Toronto, ON)

11:30 - 11:35 Welcome Remarks and Introduction

11:35 - 11:55 Where Have We Been and Where Are We Going? - Lessons Learned from a National Perspective
 ME CL LE SC

Speaker: Theresa Tam (Ottawa, ON)

By the end of this session, participants should be able to:

- Summarize where we have been and where we are going regarding the national response to COVID-19
- Define lessons learned from Canada's response to date
- Describe Canada's approach to domestic manufacturing of vaccines and personal protective equipment

12:00 - 12:30 What's Hot in Diagnostics, Genomics, and Serology
 ME CL LE SC

Speaker: Mel Krajden (Vancouver, BC)

By the end of this session, participants should be able to:

- Summarize COVID-19 diagnostic tools: NAT and antigen detection, genomics, and serology
- Define optimal use cases and specimen types for different COVID-19 diagnostic modalities

- Illustrate the usefulness of rapid sequencing in the response to COVID-19

12:35 - 13:05 What's Hot in Transmission/ Public Health/Infection Control
 ME CM CL LE SC

Speaker: Dominik Mertz (Hamilton, ON)

By the end of this session, participants should be able to:

- Review the science regarding SARS-CoV-2 transmission
- Discuss the science regarding SARS-CoV-2 infection control and public health measures
- Recognize the challenges of balancing infection control and public health guidance and buy-in from health care workers and the public

13:10 - 13:40 What's Hot in Treatment
 ME CM CL LE SC

Speaker: Srinivas Murthy (Vancouver, BC)

By the end of this session, participants should be able to:

- Review the evidence behind COVID-19 treatment options
- Describe the Canadian arm of the WHO's Solidarity Therapeutics Trial
- Discuss the challenges of navigating treatment guidance in light of politics, press releases, social media, and pre-peer review manuscripts

13:40 - 14:00 Panel Question and Answer

PROGRAM

(all times indicated in Canadian Eastern time zone)

Monday, April 26

14:00 - 14:15 Health Break

**14:15 - 15:15
 State of the Art (START)
 Clinical Lecture**

**ME CL LE SC What's Hot in COVID-19:
 Vaccines and Immunity**

Auditorium: Main Auditorium

Moderators: Robert Kozak (Toronto, ON)
 Susan Poutanen (Toronto, ON)

Speaker: Joanne Langley (Halifax, NS)

By the end of this session, participants should be able to:

- Review the effectiveness and adverse events associated with different COVID-19 vaccines

- Describe Canada's approach to COVID-19 vaccine approval, priority group determination, administration, and lessons learned from regional and international approaches

- Describe the impact of variants of concern and expected vaccine effectiveness

**16:00 - 18:00 Live Interaction
 Poster Presenters at Posters**

Location: Poster Hall

**16:00 - 18:00 Live Interaction
 Exhibitors at Exhibit Booths**

Location: Exhibit Hall

Tuesday, April 27

**On Demand Poster Viewing
 On Demand Exhibit Hall**

**11:30 - 14:00
 Plenary: Tuberculosis Update**

Auditorium: Main Auditorium

Moderators: Earl Rubin (Montréal, QC)
 Yoko Schreiber (Sioux Lookout, ON)

**11:30 - 12:10 Morphology, Resistance
 and Decolonizing TB**

**ME CM CL HA
 SC PR**

Speaker: Kathleen McMullin
 (Prince Albert, SK)

By the end of this session, participants should be able to:

- Increase awareness of the roots of TB inequities for Indigenous Peoples of Canada within a socio-historic and structural perspective
- Promote identification of concrete actions furthering Indigenous self-determination and why it is case-critical for mitigating disproportionate suffering associated with TB

- Spark insight on ways in which integrative knowledge translation between Indigenous wellness systems and conventional TB interventions increase TB program efficacy

12:10 - 12:45 Advances in TB Diagnostics

ME CM CL SC

Speaker: Marcel Behr (Montréal, QC)

By the end of this session, participants should be able to:

- Compare the advantages and limitations of nucleic acid amplification to diagnose TB
- Discuss how whole genome sequencing is being applied to the diagnosis of TB
- Appreciate how all new methods require appropriate laboratory controls

PROGRAM

(all times indicated in Canadian Eastern time zone)

Tuesday, April 27

12:45 - 13:25 Treatment of latent TB. Recent advances in new shorter regimens, and new recommendations - by the World Health Organization, and the Centres for Disease Control

ME CL LE SC

Speaker: Dick Menzies (Montréal, QC)

By the end of this session, participants should be able to:

- Understand the advantages of the new shorter Latent TB treat regimens compared to the previously recommended treatment with 9 months Isoniazid (9INH)
- Weigh the relative benefits and risk of three alternative short latent TB treatment regimens - be better informed about which regimen would be best suited to which types of patients
- Review the latest recommendations for treatment of latent TB from two authoritative agencies - the World Health Organization, and the Centres for Disease Control (US)

13:25 - 14:00 Tuberculosis from birth to adolescence

ME CL LE SC

Speaker: Ian Kitai (Toronto, ON)

By the end of this session, participants should be able to:

- Recognize the common clinical presentation of TB at different ages
- Understand the epidemiology of paediatric TB in Canada and the world including gaps in knowledge
- Recognize the unique vulnerability of young infants to TB disease and the management of the infant born to a mother who has TB disease

14:00 - 14:30 Health Break

14:30 - 15:45 Oral Presentations - Sessions A

Auditorium: Main Auditorium

Moderator: Jennifer Tam (Vancouver, BC)

A01

Incidence and timing of prosthetic joint infections following primary and revision arthroplasty: a population-based retrospective cohort study

C Kandel¹, N Daneman², J Widdifield^{3,4,5}, BE Hansen⁶, R Jenkinson^{7,8}, A McGeer⁹

¹University of Toronto, Toronto, ON; ²Sunnybrook Health Sciences Centre, Toronto, ON; ³Sunnybrook Research Institute, Holland Bone & Joint Program, Toronto, ON; ⁴Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON; ⁵ICES, Toronto, ON; ⁶Division of Gastroenterology, Toronto General Hospital, University Health Network, Toronto, ON; ⁷Division of Orthopaedic Surgery, Department of Surgery, University of Toronto, Toronto, ON; ⁸Division of Orthopaedic Surgery, Sunnybrook Health Sciences Centre, Toronto, ON; ⁹Sinai Health System, Toronto, ON

A02

Clinical characteristics, management, and outcomes of patients with indeterminate *Clostridioides difficile* tests using a modified 2-step algorithm

LE Burnes¹, SW Smith^{1,2}, K Kowalewska-Grochowska^{1,3}, JZ Chen^{1,2}

¹University of Alberta, Edmonton, AB; ²University of Alberta Hospital, Edmonton, AB; ³Provincial Laboratory of Public Health (Microbiology), Edmonton, AB

A03

Urinary tract infection investigation and treatment in older adults presenting to the emergency department with confusion - A health record review of local practice patterns

RAM Pinnell¹, T Ramsay², HX Wong³, P Joo^{2,3}

¹Department of Medicine, University of Ottawa, Ottawa, ON; ²Ottawa Hospital Research Institute, Ottawa, ON; ³Department of Family Medicine, University of Ottawa, Ottawa, ON

PROGRAM

(all times indicated in Canadian Eastern time zone)

Tuesday, April 27

A04

Impact of Cobas® PCR Media freezing on SARS-CoV-2 viral RNA integrity and whole genome sequencing analyses

P Benoit¹, F Point², S Gagnon³, D Kaufmann^{1,2,3},
 C Tremblay^{1,2,3}, RP Harrigan⁴, I Hardy^{1,2,3},
 F Coutlée^{1,2,3}, S Grandjean-Lapierre^{1,2,3}

¹Université de Montréal, Montréal, QC; ²Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC; ³Centre Hospitalier de l'Université de Montréal, Montréal, QC; ⁴University of British Columbia, Vancouver, BC

14:30 - 15:45 Oral Presentations - Sessions B

Auditorium: Main Auditorium

Moderator: Peter Daley (St. John's, NL)

B01

Verification of the New bioMérieux Piperacillin/Tazobactam E-Test® against reference broth microdilution

P Lagacé-Wiens^{1,2}, HJ Adam^{1,2}, C Turenne^{1,2},
 M Stein^{1,2}, A Walkty^{1,2}, JA Karlowsky^{1,2}

¹Shared Health, Winnipeg, MB; ²University of Manitoba, Winnipeg, MB

B02

Performance of matrix-assisted laser desorption/ionization time of flight mass spectrometry for identification of filamentous molds using several different extraction methods

L Li^{1,2}, E Bryce^{1,2}, B Velapatino², R Najafi³,
 L Kishi³, B Wang⁴, C Swanston⁴, L Hoang^{2,5},
 V Tang³, M Charles^{1,2}

¹Division of Medical Microbiology and Infection Prevention and Control, Vancouver General Hospital, Vancouver, BC; ²Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; ³Provincial Health Services Authority, Vancouver, BC; ⁴Division of Medical Microbiology, Kelowna General Hospital, Kelowna, BC; ⁵BC Centre for Disease Control, Vancouver, BC

B03

Evaluation of isavuconazole gradient strips for susceptibility testing of Mucorales isolates

L Feng¹, L Turnbull², B Jansen², TC Dingle^{1,2}

¹University of Alberta, Edmonton, AB; ²Alberta Precision Laboratories, Edmonton, AB

B04

Evaluation of whole genome sequencing-based subtyping methods for the surveillance of *Shigella flexneri* and *Shigella sonnei* and the confounding effect of mobile genetic elements in propagated outbreaks

I Bernaquez¹, C Gaudreau^{2,3}, PA Pilon^{4,5},
 F Doualla-Bell¹, D Roy¹, S Bekal^{1,3}

¹Laboratoire de santé publique du Québec, Sainte-Anne-de-Bellevue, QC; ²Microbiologie médicale et infectiologie, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC; ³Département de microbiologie, infectiologie et immunologie, Université de Montréal, Montréal, QC; ⁴Direction régionale de santé publique, Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l'Île-de-Montréal, Montréal, QC; ⁵Département de médecine sociale et préventive, Université de Montréal, Montréal, QC

17:30 - 19:30 Merit and Association Awards Masters of Ceremony:

Sarah Forgie, AMMI Canada President

Tanis Dingle, CACMID President

Curtis Cooper, CFID President

Auditorium: Unaccredited Presentations

Following the Awards Ceremony, you are invited to join the Awards Chatroom (located inside the Friendly Chat Networking Lounge) to virtually meet and congratulate the recipients and mingle and catch up with fellow attendees.

Merit and Association Awards Ceremony

Tuesday, April 27
17:30 – 19:30

Masters of Ceremony:

Sarah Forgie, AMMI Canada President
Tanis Dingle, CACMID President
Curtis Cooper, CFID President

Auditorium: Unaccredited Presentations

**ASSOCIATION OF MEDICAL
MICROBIOLOGY AND
INFECTIOUS DISEASE
CANADA AWARDS**

**AMMI Canada Distinguished
Service Award**

2019 – Daniel Gregson

**AMMI Canada Lifetime
Achievement Award**

2019 – Jay Keystone

**AMMI Canada Young Investigator
Award**

2019 – Manish Sadarangani

2020 – Matthew Cheng

**AMMI Canada Trainee Research
Award**

2019 – Samuel Chorlton

2020 – Alice Zhabokritsky

JAMMI Trainee Scientific Article Award

2020 – Brittany Kula

**AMMI Canada / bioMérieux
Post Residency Fellowship in
Microbial Diagnostic**

2020 – Jonathon Kotwa

**CANADIAN ASSOCIATION
OF CLINICAL MICROBIOLOGY
AND INFECTIOUS
DISEASES AWARDS**

**John G. FitzGerald – CACMID Out-
standing Microbiologist Award**

2020 – Michael Mulvey

2021 – Allison McGeer

**bioMérieux Award for Leadership
in Syndromic Infectious Disease
Testing Award**

2021 – Marek Smieja

**CANADIAN FOUNDATION
FOR INFECTIOUS
DISEASES AWARDS**

Dr. John M. Embil Mentorship Award

2020 – Marcel Behr

2021 – Todd Lee

**Dr. Juan A. Embil Award of Excellence
in Infectious Diseases Research**

2020 – Alexander Lawandi

2021 – Georges Ambaraghassi

**CFID Undergraduate Summer
Research Grant**

2020 - Jonathan Chung and Leslie Fell

2021 - Amaanat Gill and Sayed Zain Ahmad

**AMMI Canada Medical Student
Research Awards**

2020 – Emma Finlayson-Trick and

Marissa Nahirney

**AMMI Canada – CFID Medical
Student Research Award**

2021 – Vinyas Harish

**altona Diagnostics Canada Medical
Student Research Award**

2020 - Siena Davis

2021 - Sonia Igboanugo

**Following the Awards Ceremony, you are invited to join the Awards
Chatroom (located inside the Friendly Chat Networking Lounge) to
virtually meet and congratulate the recipients and mingle and catch up
with fellow attendees.**

PROGRAM

(all times indicated in Canadian Eastern time zone)

Wednesday, April 28

On Demand Poster Viewing

On Demand Exhibit Hall

11:00 – 12:00 Strategic Deployment of COVID-19 Treatment Options: Who, What, Where and How?

ME CL HA SC

Auditorium: Co-developed Presentations

Moderators: William Connors (Vancouver, BC)
Marthe Charles (Vancouver, BC)

Speakers: Lynora Saxinger (Edmonton, AB)
Emily McDonald (Montreal, QC)
Zain Chagla (Hamilton, ON)

By the end of the session the participants will be able to:

- Review risk factors for development and progression of COVID-19 and the impact of vaccination
- Implement the use of therapeutics in outpatients with COVID-19, including how to deploy them and to whom
- Discuss the strategic use of therapeutics in inpatients with COVID-19

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Gilead and was planned to achieve scientific integrity, objectivity and balance.

12:00 – 13:00 State of the Art (START) Clinical Lecture

ME CL SC

Bacteriophages – Solution to Antimicrobial Resistance?

Auditorium: Main Auditorium
Moderator: William Connors (Vancouver, BC)
Speaker: Steffanie Strathdee (San Diego, CA)

By the end of this session, participants should be able to:

- Understand the biology behind phage therapy
- Appreciate the complexities of phages and phage therapy
- Predict how phage therapy can fail

13:00 – 13:15 Health Break

13:15 – 14:15 State of the Art (START) Clinical Lecture

ME CL LE

Use of Artificial Intelligence to Detect and Control Epidemics

Auditorium: Main Auditorium
Moderator: Prameet Sheth (Kingston, ON)
Speaker: Kamran Khan (Toronto, ON)

By the end of this session, participants should be able to:

- Describe a high-level overview of big data and machine learning
- Discuss potential applications of machine learning in microbiology & infectious diseases
- Demonstrate how machine learning and natural language processing have been used to build a global epidemic early warning system

14:15 – 14:30 Health Break

14:30 – 15:45 Oral Presentations – Sessions C

Auditorium: Main Auditorium
Moderator: Susy Hota (Toronto, ON)

C01

Children hospitalized with community-acquired pneumonia complicated by effusion: A single-centre, retrospective cohort study

G Alemany, CSJ Lee, JM Pernica
McMaster University, Hamilton, ON

C02

Highest prevalence of *Mycoplasma genitalium* infection among other sexually transmitted diseases and macrolide and fluoroquinolone resistance mediating mutations: A Saskatchewan perspective

NR Parmar^{1,2}, L Mushanski³, T Wanlin², A Lepe^{1,2}, A Lang³, J Minion³, JR Dillon^{1,2}

¹University of Saskatchewan, SK; ²Vaccine and Infectious Disease Organization, SK; ³Saskatchewan Health Authority, Roy Romanow Provincial Laboratory, SK

PROGRAM

(all times indicated in Canadian Eastern time zone)

Wednesday, April 28

C03

Population level compliance with provincial treatment guidelines for the management of gonorrhea in Alberta, Canada, 2000-2019

A Ugarte Torres¹, C Diaz Pallarez², J Niruban³, P Smyczek³, D Strong⁴, J Gratrix³, AE Singh⁵

¹Division of Infectious Diseases, University of Calgary, Calgary, AB; ²Department of Medicine, University of Calgary, Calgary, AB; ³STI Centralized Services, Alberta Health Services, Edmonton, AB; ⁴Department of Community Health Services, University of Calgary, Calgary, AB; ⁵Division of Infectious Diseases, University of Alberta, Edmonton, AB

C04

Cerebrospinal fluid shunt infections in children: a descriptive cohort study of Canadian and US patients 2013-2019

A McAlpine¹, M Barton², A Balamohan³, HD Davies⁴, G Skar⁴, MA Lefebvre⁵, D Freire⁶, NMA Le Saux⁷, J Bowes⁸, JA Srigley¹, P Passarelli⁹, J Bradley⁹, S Khan¹⁰, R Purewal¹¹, I Viel-Thériault¹², A Ranger², JL Robinson¹³

¹BC Children's Hospital, Vancouver, BC; ²Victoria Hospital, London, ON; ³Arkansas Children's Hospital, Little Rock, Arkansas, USA; ⁴University of Nebraska, Omaha, Nebraska, USA; ⁵Montréal Children's Hospital, Montréal, QC; ⁶University of Alberta, Alberta, AB; ⁷University of Ottawa, Ottawa, ON; ⁸Children's Hospital of Eastern Ontario, Ottawa, ON; ⁹Rady Children's Hospital, San Diego, California, USA; ¹⁰McMaster Children's Hospital, Hamilton, ON; ¹¹Jim Pattison Children's Hospital, Saskatoon, SK; ¹²CHU de Québec, Québec City, QC; ¹³University of Alberta, Edmonton, AB

14:30 – 15:45 Oral Presentations – Sessions D

Auditorium: Main Auditorium

Moderator: Muhammad Morshed (Vancouver, BC)

D01

Impact of antibiotic prescribing feedback to high volume primary care physicians: A randomized controlled trial

KL Schwartz^{1,2,3}, N Ivers⁴, BJ Langford¹, M Taljaard⁵, D Neish⁶, KA Brown¹, V Leung¹, N Daneman⁷, J Alloo⁸, M Silverman⁹, E Shing¹, J Grimshaw⁵, JA Leis⁷, JHC Wu¹, G Garber¹

¹Public Health Ontario, Toronto, ON; ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON; ³Unity Health Toronto, Toronto, ON; ⁴Women's College Hospital, Toronto, ON; ⁵Ottawa Hospital Research Institute, Toronto, ON; ⁶IQVIA, Montréal, QC; ⁷Sunnybrook Research Institute, Toronto, ON; ⁸Ontario Medical Association, Toronto, ON; ⁹London Health Sciences Centre, Toronto, ON

D02

Molecular and epidemiological characterization of Adult Healthcare (HA) and Community-Associated (CA) *Clostridioides difficile* infections 2015-2019, Canada

T Du¹, K Baekyung Choi², R Hizon¹, A Silva², L Pelude², J Brooks^{2,3}, GN Al-Rawahi⁴, JC Collet⁴, B Chow⁵, JL Comeau⁶, I Davis⁷, GA Evans⁸, C Frenette⁹, G Han¹⁰, SS Hota¹¹, J Johnstone¹², KC Katz¹³, P Kibsey¹⁴, J Langley⁶, BE Lee¹⁵, Y Longtin¹⁶, D Mertz¹⁷, J Minion¹⁸, M Science¹⁹, J Srigley⁴, P Stagg²⁰, KN Suh³, N Thampi²¹, AHM Wong²², on behalf of the Canadian Nosocomial Infection Surveillance Program (CNISP)

¹National Microbiology Laboratory, Winnipeg, MB; ²Public Health Agency Canada, Ottawa, ON; ³The Ottawa Hospital, Ottawa, ON; ⁴BC Children's Hospital and BC Women's Hospital & Health Centre, Vancouver, BC; ⁵Alberta Health Services, Calgary, AB; ⁶IWK Health Centre, Halifax, NS; ⁷QEII Health Sciences Centre, Halifax, NS; ⁸Kingston General Hospital, Kingston, ON; ⁹McGill University Health Centre, Montréal, QC; ¹⁰Provincial Health Services Authority, Vancouver, BC; ¹¹University Health Network, Toronto, ON; ¹²Sinai Health System, Toronto, ON; ¹³North York General Hospital, Toronto, ON; ¹⁴Royal Jubilee Hospital, Victoria, BC; ¹⁵Stollery Children's Hospital, Edmonton, AB; ¹⁶SMBD-Jewish General Hospital, Montréal, QC; ¹⁷McMaster University and Hamilton Health Sciences, Hamilton, ON; ¹⁸Regina General Hospital, Regina, SK; ¹⁹Hospital for Sick Children, Toronto, ON; ²⁰Western Memorial Hospital, Corner Brook, NL; ²¹Children's Hospital of Eastern Ontario, Ottawa, ON; ²²Royal University Hospital, Saskatoon, SK

D03

Optimizing the treatment of *Staphylococcus aureus* bloodstream infection with the implementation of a molecular assay and antimicrobial stewardship intervention

Hilal Al Sidairi^{1,2}, EK Reid³, N Sandila⁴, J LeBlanc^{2,3}, I Davis^{2,3}, PE Bonnar^{2,3}

¹Ibri Referral Hospital, Ministry of Health, Ibri, Oman; ²Dalhousie University, Halifax, NS; ³Nova Scotia Health, Halifax, NS; ⁴Research Methods Unit, Nova Scotia Health, Halifax, NS

D04

Assessment of empirical vancomycin use and appropriateness at a tertiary care pediatric hospital

K Alsager¹, J Vayalumkal², C Constantinescu³

¹Pediatric Antimicrobial Stewardship Fellow, University of Calgary, Calgary, AB; ²Section of Infectious Diseases, Department of Pediatrics, University of Calgary, Calgary, AB; ³Pediatric Infectious Disease, Clinical Assistant Professor, University of Calgary, Calgary, AB

15:45 – 18:00 Live Interaction Poster Presenters at Posters

Location: Poster Hall

15:45 – 18:00 Live Interaction Exhibitors at Exhibit Booths

Location: Exhibit Hall

PROGRAM

(all times indicated in Canadian Eastern time zone)

Thursday, April 29

On Demand Poster Viewing
On Demand Exhibit Hall

11:30 - 13:30

Plenary: Clinical Controversies

Auditorium: Main Auditorium
Moderators: Titus Wong (Vancouver, BC)
 Manish Sadarangani (Vancouver, BC)

11:30 - 12:30 **Mandatory Childhood Immunization: Should We Debate This or Consider Our Options?**

(co-developed by CAIRE: Canadian Association for Immunization, Research, Evaluation and Research)

Speakers: Noni MacDonald (Halifax, NS)
 Monika Naus (Vancouver, BC)

By the end of this session, participants should be able to:

- Review the concepts related to mandatory childhood immunization
- Describe the impact of COVID-19 on uptake of childhood immunization and its potential implications and solutions, including the role of 'mandatory' models

12:30 - 13:30 **To Screen or Not to Screen: VRE-Evaluating the Data**

Debaters: Jennie Johnstone (Toronto, ON)
 – **For hospital IPAC programs screening for VRE**
 Stephanie Smith (Edmonton, AB)
 – **Against hospital IPAC programs screening for VRE**

Resolution: Be it resolved that hospital Infection Prevention and Control programs should no longer screen for VRE

By the end of this session, participants should be able to:

- Define the clinical impact of VRE infection and understand the changing clinical epidemiology of VRE in Canadian hospitals
- Discuss the evidence for and against VRE control programs
- Recognize the gaps in knowledge around VRE prevention and control

13:30 - 15:00 **Live Interaction**
Exhibitors at Exhibit Booths

Location: Exhibit Hall

15:00 - 16:15 **Oral Presentations - Session E**

Auditorium: Main Auditorium
Moderator: Vanessa Tran (Toronto, ON)

E01

Waning anti-nucleocapsid IgG signal among SARS-CoV-2 seropositive blood donors: May- November 2020

S Saeed¹, SJ Drews^{2,3}, C Pambrun⁴, SF O'Brien¹

¹Canadian Blood Services, Epidemiology and Surveillance, Ottawa, ON; ²Canadian Blood Services, Microbiology, Edmonton, AB; ³University of Alberta, Department of Laboratory Medicine and Pathology, Edmonton, AB; ⁴Canadian Blood Services, Medical Affairs and Innovation, Ottawa, ON

E02

SARS-CoV-2 Serology: Validation of high-throughput Chemoluminescent Immunassay (CLIA) platforms and a field study in British Columbia

AS Mak¹, I Sekirov¹, D Cook¹, P Levett¹, A Jassem¹, MG Morshed¹, A Olmstead¹, V Barakauskas², J Simons³, S Masood⁴, M Charles⁵, A Hayden⁶, M Krajden¹

¹BC Center for Disease Control, Vancouver, BC; ²Children's and Women's Hospital, Vancouver, BC; ³St. Paul's Hospital, Providence Health, Vancouver, BC; ⁴Surrey Memorial Hospital, Surrey, BC; ⁵Vancouver General Hospital, Vancouver, BC; ⁶Vancouver Coastal Health Authority, Vancouver, BC

PROGRAM

(all times indicated in Canadian Eastern time zone)

Thursday, April 29

E03

Analysis of the performance of water gargle samples for SARS-CoV-2 detection using heat extraction followed by laboratory-developed nucleic acid amplification testing

S Gobeille Paré¹, J Bestman-Smith¹, J Fafard², F Doualla-Bell², M Jacob-Wagner¹, M St-Hilaire³, S Beauchemin³, V Boucher⁴, F Vancol-Fable³, C Lavallée³, AC Labbé^{3,5,6}

¹Centre Hospitalier Universitaire de Québec - Université Laval, Québec, QC; ²Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC ³CIUSSS de l'Est-de-l'Île-de-Montréal, Montréal, QC; ⁴Centre Hospitalier Universitaire de Québec - Université Laval Research Center, Québec, QC; ⁵Centre Hospitalier Universitaire de Montréal, Montréal, QC ⁶Université de Montréal, Montréal, QC

E04

Saliva assay for viral examination of SARS-CoV-2 (SAVE-CoV): A pilot study

SM Poutanen^{1,2}, C Lemieux^{2,3}, B Hazlett¹, M Landes^{2,3}, A McGeer^{1,2}, TT Mazzulli^{1,2}, S Friedman^{2,3}

¹University Health Network/Sinai Health System, Toronto, ON; ²University of Toronto, Toronto, ON; ³University Health Network, Toronto, ON

**16:15 - 18:00 Live Interaction
 Poster Presenters at Posters**

Location: Poster Hall

Friday, April 30

**10:00 - 12:00 Live Interaction
 Poster Presenters at Posters**

Location: Poster Hall

**10:00 - 12:00 Live Interaction
 Exhibitors at Exhibit Booths**

Location: Exhibit Hall

**12:30 - 13:30
 State of the Art (START)
 Clinical Lecture**

**ME CM CL HA Zoonoses and Preparedness
 in the Anthropocene**

Auditorium: Main Auditorium

Moderator: Robert Kozak (Toronto, ON)

Speaker: Craig Stephen (Nanose Bay, BC)

By the end of this session, participants should be able to:

- Discuss the drivers of emerging zoonotic infections, how they are being affected in the Anthropocene and their implications for future research and knowledge mobilization.
- Propose a 5-step pathway to rising to the challenges of emerging zoonoses in these times of unprecedented change and accelerating exceptions to prevent the next pandemic

13:30 - 13:45 Health Break

PROGRAM

(all times indicated in Canadian Eastern time zone)

Friday, April 30

13:45 – 15:45

Plenary: What's Hot in Adult and Paediatric Infectious Diseases, Infection Control and Diagnostic Microbiology?

(co-developed by CFID: Canadian Foundation for Infectious Diseases)

Auditorium: Main Auditorium

Moderators: Shariq Haider (Hamilton, ON)
 David Patrick (Vancouver, BC)

13:45 – 14:15 What's Hot in Adult Infectious Disease

ME CM

Speaker: Natasha Press (Vancouver, BC)

By the end of this session, participants should be able to:

- Describe recent new findings that impact the practice of adult infectious diseases

14:15 – 14:45 What's Hot in Paediatric Infectious Disease

ME CM CL

Speaker: Joan Robinson (Edmonton, AB)

By the end of this session, participants should be able to:

- Describe recent new findings that impact the practice of paediatric infectious diseases

14:45 – 15:15 What's Hot in Diagnostic Microbiology

ME CM

Speaker: David Goldfarb (Vancouver, BC)

By the end of this session, participants should be able to:

- Describe recent new findings that impact the practice of diagnostics microbiology

15:15 – 15:45 What's Hot in Infection Prevention and Control (IPAC)

ME CM

Speaker: Titus Wong (Vancouver, BC)

By the end of this session, participants should be able to:

- Describe recent new findings that impact the practice of infection prevention and control

15:45 – 16:00 Closing Remarks and Student Awards Presentations

Auditorium: Main Auditorium

Speakers: Tanis Dingle (Edmonton, AB)
 Sarah Forgie (Edmonton, AB)

POSTER AND ORAL AWARDS

Association of Medical Microbiology and Infectious Disease (AMMI) Canada Poster Award

Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID) Student Oral Presentation Award

Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID) Poster Award

Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID) Technologist Poster Award

Canadian College of Microbiologists (CCM) Poster Award

Canadian College of Microbiologists (CCM) Dr. Kenneth Rozee Memorial Poster Award

Dr. Susan King Paediatric Abstract Award

2021

April 25-30 / 25-30 avril
ANNUAL CONFERENCE
CONFÉRENCE ANNUELLE
AMMI Canada - CACMID



Vancouver

April 6 - 9, 2022



Save the date!

SPEAKER BIOGRAPHIES



MARCEL BEHR

Marcel Behr is a clinician-scientist with appointments of Full Professor in the Department of Medicine and Associate member in the departments of Epidemiology and Biostatistics as well as Microbiology and Immunology. He was the founding Director of the McGill International TB Centre and led it from 2012 to 2018. He is the Associate Program Leader of the Infectious Diseases and Immunity in Global Health Program at the Research Institute of the McGill University Health Centre since 2016 and in 2017 he became the co-Director the McGill Interdisciplinary Initiative in Infection and Immunity (McGill-i4). He is the interim director of McGill Infectious Diseases Division. Dr. Behr trained at the University of Toronto, Queen's, McGill and Stanford. His work has been recognized by election into the Canadian Academy of Health Sciences, the Royal Society of Canada, the American Society for Clinical Investigation and the American Academy of Microbiology. Dr. Behr's lab uses bacterial genomic methodologies to study the epidemiology and pathogenesis of tuberculosis and other mycobacterial diseases.

ZAIN CHAGLA


Zain Chagla is an M.D. specializing in internal medicine, tropical medicine, and infectious diseases, he is Medical Director, Infection Control, at St. Joseph's Hospital and Hamilton Health Sciences, Niagara Health, and is a consultant at Woodstock General Hospital. He is an associate Professor of Medicine at McMaster University, and adjunct faculty at the University of Namibia in the Department of Medicine. He also received his M.Sc from the London School of Hygiene and Tropical Medicine, and a Diploma in Tropical Medicine completed in Tanzania and Uganda through the London School of Hygiene and Tropical Medicine. Dr. Chagla has been a part of COVID-19 clinical trials, infection control and testing, and epidemiology.

DAVID GOLDFARB

David Goldfarb MD FRCPC is a Clinical Associate Professor in the Department of Pathology and Laboratory Medicine at University of British Columbia and Medical Microbiologist and Pediatric Infectious Disease Physician at BC Children's Hospital. His research focuses on novel diagnostic, prevention, and management strategies for childhood infectious diseases particularly in remote and resource limited settings. He leads several research projects in sites in Africa and northern Canada.

JENNIE JOHNSTONE

Jennie Johnstone obtained her medical degree from Dalhousie University. She then moved to Edmonton, Alberta where she completed her Internal Medicine and Infectious Disease training at the University of Alberta. Following her residency, she completed a clinical research fellowship in Edmonton. She moved to Hamilton in July 2008 where she practiced Infectious Diseases at McMaster University and completed her PhD in Health Research Methodology (Epidemiology). Following her PhD, she joined Public Health Ontario as an Infection Prevention and Control physician where she continues to lead research focused on Infection Prevention and Control in the areas of vancomycin resistant enterococci, ventilator associated pneumonia and Clostridium difficile. She worked at St. Joseph's Health Center in Toronto for 5 years, where she practiced Infectious Diseases and ran the Infection Prevention and Control program. In 2018 she left St. Joseph's to become a physician co-lead of Infection Prevention and Control at Sinai Health System in Toronto where she is also an Assistant Professor in the Laboratory Medicine and Pathobiology and Dalla Lana School of Public Health, University of Toronto.



KAMRAN KHAN

Kamran Khan is an infectious disease physician-scientist and a Professor of Medicine and Public Health at the University of Toronto. Motivated by his experiences as a frontline healthcare worker during the 2003 Toronto SARS outbreak, Dr. Khan has been studying outbreaks of emerging and re-emerging diseases for more than a decade to lay the scientific foundation for a global early warning system for infectious diseases. To translate and disseminate scientific knowledge into timely action, Dr. Khan founded BlueDot in 2013, a digital health company that combines human and artificial intelligence to help governments protect their citizens, hospitals protect their staff and patients, and businesses protect their employees and customers from dangerous infectious diseases. Dr. Khan recently received a Governor General's Award for his work transcending clinical medicine, public health, big data, and artificial intelligence.

IAN KITAI

Ian Kitai is Tuberculosis Specialist at SickKids and first author of the paediatric chapter of the Canadian TB standards, as well as many publications related to childhood TB. He has worked in rural Zimbabwe with Oxfam UK and in Norway House, Manitoba with the Northern Medical Unit of University of Manitoba. He is a professor in the Department of Paediatrics at the University of Toronto.

ROBERT KOZAK

Robert Kozak completed his PhD in microbiology and immunology at McGill University. Following this he completed post-doctoral fellowships in viral hepatitis and zoonotic viruses at McGill and the Ontario Veterinary College, University of Guelph, respectively. Before entering the clinical microbiology training program at the University of Toronto, he trained at the Special Pathogens Program at the National Microbiology Laboratory in Winnipeg where he studied viral hemorrhagic fevers, and zoonotic viruses. During this time, he led teams investigating Ebola virus transmission in animals models and developing vaccines and countermeasures for Crimean Congo Hemorrhagic fever virus. Additionally, he was involved in projects investigating Middle East Respiratory Syndrome coronavirus, hantavirus

and Zika virus. He also serves on the boards of the Canadian College of Microbiologists and the Canadian Association of Clinical Microbiology and Infectious Diseases. Currently he works as a clinical microbiologist at Shared Hospital Laboratory at Sunnybrook Health Sciences Centre. Recently his research has focused on COVID-19 specifically in the areas of diagnostics, and the development and evaluation of vaccines and therapeutics.

MEL KRAJDEN

Mel Krajden MD, FRCPC is the Medical Director of the BC Centre for Disease Control Public Health Laboratory and the Medical Head of Hepatitis at the British Columbia Centre for Disease Control. He is also a Professor of Pathology and Laboratory Medicine at the University of British Columbia. He currently a member of Federal COVID Immunity Task Force and facilitates the Testing Working Party. His laboratory research involves the application of molecular techniques to diagnose viruses, assess correlates between infection and clinical disease, and track microbial infections for epidemiological purposes. His clinical research involves integration of hepatitis prevention and care services which involves the use of linked laboratory and administrative data to help understand how to measure population level health outcomes for policy making. He has extensive clinical trials expertise and has received CIHR funding in the fields of human papillomavirus, HIV, hepatitis C virus and COVID-19. He is also a Co-PI/Mentor for CIHR funded Canadian Hepatitis C Network (CanHepC) and has >300 publications.

JOANNE LANGLEY

Joanne Langley is a Professor of Pediatrics and Community Health and Epidemiology at Dalhousie University and the Canadian Center for Vaccinology in Halifax, NS Canada, head of Pediatric Infectious Diseases at the IWK Health Centre, and lead for the Clinical Trials Network of the Canadian Immunization Research Network. She currently co-chairs the Canadian COVID-19 Vaccine Task Force. Her research is focused on the epidemiology and vaccine prevention of respiratory infections, particularly Respiratory Syncytial Virus and influenza, and immunization decision making.

NONI MACDONALD

Noni MacDonald is a Professor of Paediatrics (Infectious Diseases) at Dalhousie University and the IWK Health Centre in Halifax Canada and a former Dean of Medicine at Dalhousie University. Her two current major areas of interest involve global health. The first is vaccines, including vaccine safety, hesitancy, demand, pain mitigation, education and policy especially through her work with the World Health Organization (WHO). She has been a member of SAGE (the Strategic Advisory Group of Experts on immunization for WHO) since 2017. The second area of interest is MicroResearch (www.microresearchinternational.ca), building capacity in community focused research in developing countries. She has published over 450 papers; was the founding Editor-in-Chief of Paediatrics & Child Health for over 20 years, and a former Editor-in-Chief of CMAJ (Canadian Medical Association Journal). Dr. MacDonald has long been recognized in Canada and internationally, as an advocate for children and youth health and as a leader in paediatric infectious disease and global health. She is an Officer of the Order of Canada and a recipient of the Order of Nova Scotia.

EMILY MCDONALD

Emily McDonald is an Associate Professor of Medicine in General Internal Medicine at McGill University, Scientist at the Research Institute of the McGill University Health Centre and Director of a research unit for the Department of Medicine- the Clinical Practice Assessment Unit. She completed medical school, residency and a Masters in Epidemiology at McGill University and post-graduate research training in Toronto and at the Harvard School of Public Health. She was recently named to the Canadian Task Force for Preventive Health Care and is the Associate Chair of Quality and Safety for the McGill University Department of Medicine. Dr. McDonald has helped lead several international clinical trials of repurposed medications for the treatment of COVID-19 since the pandemic began in March 2020.

KATHLEEN MCMULLIN

Kathleen McMullin is a member of the Lac La Ronge Indian Band in northern Saskatchewan and she resides in Prince Albert, Saskatchewan. Kathleen holds a Bachelor of Education degree

and a Master's degree in Indigenous and Northern Education. Currently, she is a PhD Candidate at the Department of Health Sciences, College of Medicine, University of Saskatchewan and her thesis topic is 'Standing in the Matriarchal Footsteps of our Cree Grandmothers' which is about the impact of colonization on traditional home stewardship and is a strength-based approach to revitalizing and reinforcing the culture, pride, skills and values in contemporary Indigenous homes and housing. Kathleen works part time as a Cultural Engagement Advisor for Queen's University on a CIHR funded project entitled 'Recurrent tuberculosis in Canada - translating whole genome sequence insights into best public health practice'. Prior to this study, Kathleen also worked with the Determinants of TB Project from 2006 - 2012 as a research coordinator for the University of Saskatchewan and the Tuberculosis Population Evaluation Research Unit (TBPERU), University of Alberta. Following this position, from 2011 to 2012 she was Research Manager for the TBPERU's 'Tuberculosis Education in Aboriginal and non-Aboriginal Youth: An Historical, Socio-cultural and Public Health Promotional Curriculum Project'. Then, from 2012 to 2013, Kathleen became Research Manager for the project 'Assess, Redress, Re-assess: Addressing Disparities in Respiratory Health among First Nations People' at the Canadian Centre for Health and Safety in Agriculture Research (CCHSAR), University of Saskatchewan.

DICK MENZIES

Dick Menzies received his medical training at McGill University, Montreal and specialty training in Internal Medicine at the Medical College of Pennsylvania in Philadelphia, USA. He then worked for 2 ½ years in Lesotho, Africa, where he was first exposed (literally) to tuberculosis – in all its forms, and with all its devastation. He then received sub-specialty training in Respiratory Medicine and a Master's degree in Epidemiology & Biostatistics at McGill University. Dr. Menzies served as Medical Director at the Montreal Chest Institute for a total of 10 years ending in 2002, and then as Director of the Respiratory Division for 9 years. He is now Director of the McGill International TB Centre, and the McGill WHO Collaborating Centre in TB Research.

DOMINIK MERTZ

Dominik Mertz attended medical school and completed his training in Internal Medicine and Infectious Diseases in Switzerland prior to moving to Canada to complete a Master's Degree in Health Research Methodology/ Clinical Epidemiology at McMaster University, Hamilton, ON. He is currently an Associate Professor in the Department of Medicine and is affiliated with the Departments for Health Research Methods, Evidence and Impact, the Department of Pathology and Molecular Medicine, the Population Health Research Institute (PHRI), and the Michael G. DeGroot Institute for Infectious Diseases Research at McMaster University. He is a practising infectious diseases physician and is serving as the Medical Director Infection Prevention and Control at Hamilton Health Sciences. His particular research interest is the epidemiology and prevention of hospital-acquired infections including surgical site infections, antimicrobial stewardship, and quality improvement. He published >100 peer reviewed articles to date. He is an associate editor for BMC Infectious Diseases and served as the first-named editor for the 3rd edition of the book 'Evidence-based Infectious Diseases'. He is involved in the Canadian Nosocomial Infection Surveillance Program (CNISP), the Society of Healthcare Epidemiology of America (SHEA), is a member of the AMMI Research Network steering committee and of the Ontario Provincial Infectious Diseases Advisory Committee (PIDAC). He is also serving on multiple provincial, regional and local taskforces and committees in relation to the COVID-19 pandemic.

MATTHEW MILLER

Dr. Miller is an Associate Professor, Associate Chair, and Assistant Dean in the Department of Biochemistry and Biomedical Sciences at McMaster University. He is also a member of the Michael G. DeGroot Institute for Infectious Diseases Research and the McMaster Immunology Research Centre. Dr. Miller also serves as a member of the and as Secretary-Treasurer of the Canadian Society for Virology. Dr. Miller completed his PhD in Microbiology & Immunology at the University of Western Ontario, where he studied the molecular virology and pathogenesis of DNA viruses. He went on to complete a CIHR-funded


postdoctoral fellowship with Dr. Peter Palese at the Icahn School of Medicine at Mount Sinai in New York, NY where his research focus shifted to the design of "universal" influenza virus vaccines. Dr. Miller was recruited to McMaster University in 2014 as an Assistant Professor where his research has been focused on issues related to influenza virus pandemic preparedness – especially vaccinology. He has been awarded a CIHR New Investigator Award, the CIHR Bhagirath Singh Early Career Award in Infection and Immunity, an and Early Researcher Award from the Government of Ontario. Since early 2020, Dr. Miller has been heavily engaged in COVID-19 research, including development of next-generation COVID-19 vaccines, therapeutics, and diagnostics. He serves as the SARS-CoV-2 CL3 supervisor for McMaster University and is a member of the National Advisory Committee on Immunization (NACI) High Consequence Infectious Disease Working Group, which makes recommendations to inform the use of COVID-19 vaccines in Canada.

SRINIVAS MURTHY

Srinivas Murthy is the Innovative Medicines Canada and Health Research Foundation Chair in Pandemic Preparedness Research. He is Clinical Associate Professor at the University of British Columbia in Vancouver, Canada. His research focuses on the treatment of severe infections, global outbreak response, and innovative clinical trials.


MONIKA NAUS

Monika Naus is the Medical Director of the Communicable Diseases & Immunization Service, Head of Vaccine Preventable Diseases & Immunization Programs at the British Columbia Centre for Disease Control, and Professor at the School of Population and Public Health at the University of British Columbia. Dr. Naus obtained her medical training at the University of Alberta and her training in Public Health and Preventive Medicine at the University of Toronto. She then served as a federal field epidemiologist with the Laboratory Centre for Disease Control prior to starting her career in public health, with a focus on communicable disease prevention and control. Before joining BCCDC in July 2001, she was the provincial epidemiologist in Ontario from 1997 to 2001, and a senior medical




consultant in vaccine preventable diseases and TB control for the Ontario Ministry of Health and Long-Term Care from 1990 to 1997. She has been active in immunization at the national level, including on the Canadian National Advisory Committee on Immunization, she currently co-chairs the Canadian Immunization Committee, is a member of the Canadian Immunization Registries and Coverage Network and of the Canadian Immunization Research Network and is involved in other national and provincial committees. She is a Fellow of the Royal College of Physicians of Canada and of the American College of Preventive Medicine.

GLENN PATRIQUIN



Glenn Patriquin is Haligonian and a graduate of Dalhousie University Medical School. He completed Internal Medicine residency and a combined Infectious Diseases and Medical Microbiology training program in Halifax, with a subsequent research fellowship at Sunnybrook Health Sciences Centre. He is currently co-director of the Bacteriology Laboratory and an Infectious Diseases consultant at the QEII Health Sciences Centre in Halifax.

NATASHA PRESS




Natasha Press works as an Infectious Diseases physician at St. Paul's Hospital. She graduated from the University of Toronto Medical School (1995) and completed her residency training in Internal Medicine and Infectious Diseases at the University of British Columbia. Following that, she did a research fellowship in HIV clinical trials with the Canadian HIV Trials Network. Interests include HIV care and infections related to injection drug use.


JOAN ROBINSON

Joan Robinson was the fifth generation to live on a cattle ranch near Innisfail, Alberta. Her dad and brother were rodeo cowboys, yet she is afraid of horses so had to find something else to do. She did medical school at the University of Alberta, interned at the Royal Columbian Hospital in New Westminster, did GP locums, did a pediatric residency at BC Children's Hospital and then moved back to Edmonton to train in pediatric ID. She has been on staff at the Stollery Children's Hospital since about the year that the Oilers last won a Stanley Cup which is quite long time.


LYNORA SAXINGER



Lynora Saxinger, CTropMed, MD, FRCPC, is an University of Alberta based Infectious Diseases specialist whose clinical practice includes HIV, Hepatitis C, nontransplant immunocompromised hosts, and Travel and Tropical Medicine. Her pre pandemic role is Co-Chair of the Alberta Health Services Antimicrobial Stewardship Committee, and she is involved in national Stewardship initiatives to promote best practices in antibiotic use, evaluation of surveillance of Antimicrobial Utilization and Antimicrobial Resistance through a One-Health lens, and derivation of Stewardship best practices. Her pandemic role is co-lead of the Alberta COVID-19 Scientific Advisory Group, and engagement in social media and media based scientific communication and knowledge translation for public education around COVID-19.




YOKO SCHREIBER



Yoko Schreiber completed her training and worked several years at The Ottawa Hospital / University of Ottawa, Yoko decided to move closer to communities she wished to serve and relocated to Sioux Lookout, Ontario. Yoko currently holds a position as an Assistant Professor both at NOSM and University of Manitoba, and spends her time providing general ID clinical care Sioux Lookout region, which covers over 28 remote First Nations communities, as well as spending several weeks a year in Winnipeg. Her practice spans from clinical care to assisting the local health authority with public health issues and includes research, education and involvement in national committee work (FNIHB, AMMI). In all, she considers herself the luckiest ID physician in the country, being able to practice ID in a setting where it is needed most, surrounded by lakes and outdoor opportunities in Ontario's "sunset country."

STEPHANIE SMITH



Stephanie Smith is a professor in the Division of Infectious Diseases at the University of Alberta. She is trained in adult infectious diseases and her clinical practice includes care of inpatients with complicated infections, outpatient HIV and viral hepatitis. She is Director of Infection Prevention and Control at the University Hospital and Mazankowski Heart Institute. She is involved in local, provincial and

national committees related to infection prevention and control, hospital acquired infection surveillance and prevention of antimicrobial resistance. She is involved in education of infectious diseases trainees at both the local and national level.

CRAIG STEPHEN

Craig Stephen DVM PhD, is a clinical professor at both the School of Population and Public Health (UBC) and the Ross School of Veterinary Medicine. He is an ecohealth and One Health practitioner who has worked at the interface of human, animal and environmental health for 25 years. He has worked extensively on emerging infectious diseases in Canada and in a global health context. Craig's current focus is on adapting harm reduction and health promotion concepts to develop a reciprocal care approach to health threats of the Anthropocene shared by people, animals and ecosystems. This includes promoting nature-based approaches to pandemic prevention and recovery. He has over 200 peer-reviewed and technical publications and has edited 4 books on these subjects, most recently, *Animals Health and Society: Health Promotion, Harm Reduction and Health Equity* in a One Health World.

STEFFANIE STRATHDEE

Steffanie Strathdee is a Canadian-American infectious disease epidemiologist trained at the University of Toronto. She is Associate Dean of Global Health Sciences and Harold Simon Professor of Medicine at the University of California San Diego where she codirects the Center for Innovative Phage Applications and Therapeutics (IPATH), and Adjunct Professor at Johns Hopkins and Simon Fraser Universities. In 2016, Strathdee and colleagues were credited with saving her husband's life from a deadly superbug infection using bacteriophages – viruses that attack bacteria. The case, which involved cooperation from three universities, the U.S. Navy and researchers across the globe, shows how phage therapy is a future weapon against multi-drug resistant bacterial infections which are expected to kill

10 million people per year by 2050. Strathdee co-authored a book on their story called *The Perfect Predator: A Scientist's Race to Save Her Husband from a Deadly Superbug*. For her efforts to revitalize phage therapy in the West, she was named one of TIME magazine's Most Influential People in Health Care in 2018.

THERESA TAM

Theresa Tam was named Canada's Chief Public Health Officer (CPHO) on June 26, 2017. She is a physician with expertise in immunization, infectious disease, emergency preparedness and global health security. As the federal government's lead health professional, Dr. Tam provides advice to the Minister of Health, supports and provides advice to the President of the Public Health Agency of Canada, and works in collaboration with the President in the leadership and management of the Agency. The Public Health Agency of Canada Act empowers the CPHO to communicate with other levels of government, voluntary organizations, the private sector and Canadians on public health issues. Each year, the CPHO is required to submit a report to the Minister of Health on the state of public health in Canada.

TITUS WONG

Titus Wong completed his MD and Medical Microbiology residency at the University of British Columbia and earned a Master's in Health Science (Clinical Epidemiology) from the UBC School of Population and Public Health. Titus joined the Division of Medical Microbiology and Infection Prevention at Vancouver Coastal Health (VCH) in 2012 and currently serves as the Regional Medical Director for Infection Prevention and Control at VCH and as the co-Medical Director of the BC Provincial Infection Control Network with the Provincial Health Services Network. Titus has research interests in the testing and clinical application of environmental infection control strategies and has been working tirelessly with the IPAC team to support the pandemic response in British Columbia.

E-POSTERS

On Demand starting Sunday, April 25
Poster Hall



PO1

OPAT quality indicators at a tertiary care centre reveal vast room for improvement

JL Martinez-Cajas¹, S McKenna², B Alvarado-Llano¹, E Wilson¹, K Leifso¹, S Perez-Patrigéon¹, GA Evans¹

¹Queen's University, Kingston, ON; ²Kingston Health Sciences Centre, Kingston, ON

PO2

Outcomes of a risk-based decision-making process for reducing the risk of Hepatitis E virus transfusion transmission via the Canadian blood supply

S Ward¹, G Delage², Y Gregoire³, G Hawes⁴, C Brennan¹, L Potter¹, M Fearon⁵, C Simpson^{6,7,8}, M McDonald^{7,9}, B Knoppers^{7,10}, S O'Brien¹, SJ Drews^{11,12}

¹Canadian Blood Services, Ottawa, ON; ²Héma-Québec, Saint-Laurent, QC; ³Héma-Québec, Quebec City, QC; ⁴Canadian Blood Services, Brampton, ON; ⁵Canadian Blood Services, Toronto, ON; ⁶Dalhousie University, Halifax, NS; ⁷Canadian Blood Services Bioethics Advisory Committee, Ottawa, ON; ⁸Canadian Blood Services Bioethics Consultant, Halifax, NS; ⁹University of British Columbia, Vancouver, BC; ¹⁰McGill University, Montréal, QC; ¹¹Canadian Blood Services, Edmonton, AB; ¹²Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB

Live Interaction, Poster Presenters at Posters

*participation by presenters may vary

Monday, April 26	16:00 – 18:00 EDT
Wednesday, April 28	15:45 – 17:45 EDT
Thursday, April 29	16:15 – 18:00 EDT
Friday April 30	10:00 – 12:00 EDT

P03

Evaluation of the NG-Test Carba 5 Multiplex Immuno-chromatographic Assay and Cepheid Xpert Carba-R Assay for the detection of Carbapenemase genes in gram negative organisms

GN Al-Rawah^{1,2}, R Penny¹, A Cuarte¹, S Dhaliwal¹, T Chen¹, D Purych^{2,3}, D Boyd⁴, L Hoang^{2,5}, P Tilley^{1,2}

¹BC Children's Hospital, Vancouver, BC; ²University of British Columbia, Vancouver, BC; ³Fraser Health, Surrey, BC; ⁴Public Health Agency of Canada, Winnipeg, MB; ⁵Public Health Microbiology and Reference Laboratory, Vancouver, BC

P04

SARS-CoV-2 transmission through cells, tissues and organs transplantation

A Gausse¹, L Hornby^{2,3}, G Rockl¹, S O'Brien³, G Delage⁴, R Sapir-Pichhadze^{5,6,7}, SJ Drews^{8,9}, MJ Weiss^{10,11,12}, A Lewin^{4,13}

¹Medical Affairs and Innovation, Héma-Québec, Québec, QC; ²Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON; ³Canadian Blood Services, Ottawa, ON; ⁴Medical Affairs and Innovation, Héma-Québec, Saint-Laurent, QC; ⁵Centre for Outcomes Research and Evaluation (CORE), Research Institute of McGill University Health Centre, Montréal, QC; ⁶Division of Nephrology and the Multi Organ Transplant Program, Royal Victoria Hospital, McGill University Health Centre, Montréal, QC; ⁷Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, QC; ⁸Canadian Blood Services, Edmonton, AB; ⁹Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB; ¹⁰Population Health and Optimal Health Practices Research Unit, Trauma-Emergency-Critical Care Medicine, CHU de Québec, Université Laval Research Center, Québec, QC; ¹¹Pediatrics Department, Intensive Care Division, Faculté de Médecine, Université Laval, Québec, QC; ¹²Transplant Québec, Montréal, QC; ¹³Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC

P05

One Health genomic study of extended spectrum beta-lactamases (ESBL)-producing *Salmonella enterica* in Canada, 2012-2016A Bharat^{1,2}, L Mataseje¹, EJ Parmley^{3,4}, BP Avery⁴, G Cox^{1,2}, C Carson⁴, RJ Irwin⁴, AE Deckert⁴, D Daignault⁵, DC Alexander⁶, VG Allen⁷, S El Bailey⁸, S Bekal⁹, L Chui¹⁰, GJ German¹¹, D Haldane¹², L Hoang¹³, J Minion¹⁴, G Zahariadis¹⁵, RJ Reid-Smith⁴, MR Mulvey¹¹National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; ²Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB; ³Department of Population Medicine, University of Guelph, Guelph, ON; ⁴Centre for Food-borne, Environmental and Zoonotic Infectious Diseases, Public Health Agency of Canada, Guelph, ON; ⁵National Microbiology Laboratory, Public Health Agency of Canada, St. Hyacinthe, QC; ⁶Cadham Provincial Laboratory, Winnipeg, MB; ⁷Public Health Ontario Laboratories, Toronto, ON; ⁸Horizon Health Network, Saint John, NB; ⁹Laboratoire de santé publique du Québec, Sainte-Anne-de-Bellevue, QC; ¹⁰Alberta Precision Laboratories-Provincial Laboratory for Public Health, Edmonton, AB; ¹¹Queen Elizabeth Hospital, Charlottetown, PE; ¹²Queen Elizabeth II Health Sciences Centre, Halifax, NS; ¹³British Columbia Centres for Disease Control, Vancouver, BC; ¹⁴Roy Romanow Provincial Laboratory, Regina, SK; ¹⁵Newfoundland and Labrador Public Health and Microbiology Laboratory, St. John's, NL

P06

Canadian cost-utility analysis of isavuconazole for the treatment of patients with invasive aspergillosis and mucormycosisC Beauchemin^{1,2}, K Guinan¹, K Mathurin^{1,2}, S Frédéric Dufresne³, C Rotstein⁴, D Claveau⁵, L Landry⁵, J Lachaine^{1,2}¹PeriPharm Inc., Montréal, QC; ²Faculté de Pharmacie, Université de Montréal, Montréal, QC; ³Department of Infectious Diseases and Medical Microbiology, Maisonneuve-Rosemont Hospital Research Center, Université de Montréal, Montréal, QC; ⁴Immunocompromised Host Infectious Diseases Service, Division of Infectious Diseases, Department of Medicine, University Health Network, University of Toronto, Toronto, ON; ⁵AVIR Pharma Inc., Blainville, QC

P07

A virtual care model utilizing patient directed oximetry monitoring for outpatients with COVID-19: A quality improvement studyMK Devlin^{1,2}, MJ Nicholson^{1,2}, JA Ernst^{1,3}, I Dhaliwal^{1,3}, M Mrkobrada^{1,3}, E Spicer^{1,3}¹Western University, London, ON; ²St. Joseph's Health Centre, London, ON; ³London Health Sciences Centre, London, ON

P08

Case report: *Actinotignum schaalii* identified in a neck abscess of a pediatric patientRM Kariyawasam^{1,2}, EM Morin³, E Eksteen⁴, K Kowalewska-Grochowska^{1,2,5}¹Division of Diagnostic & Applied Microbiology, Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, AB; ²Alberta Precision Labs-Public Health, Edmonton, AB; ³Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Alberta, Edmonton, AB; ⁴Division of Otolaryngology, Department of Surgery, University of Alberta, Edmonton, AB; ⁵Division of Medical Microbiology & Immunology, Department of Medicine, University of Alberta, Edmonton, AB

P09

Synergistic activity of combinations of colistin with other antibiotics against multidrug- and extensively drug resistant clinical isolates of *Klebsiella pneumoniae*, *Acinetobacter baumannii* and *Pseudomonas aeruginosa*

TA Petrovskaya, DV Tapalski

Gomel State Medical University, Gomel, Belarus

P10



The vancomycin minimum inhibitory concentration of *Staphylococcus* species isolated from children's blood cultureEYH Yeung^{1,2}, NMA Le Saux³¹University of Ottawa, Ottawa, ON; ²Eastern Ontario Regional Laboratory Association, Ottawa, ON; ³Children's Hospital of Eastern Ontario, Ottawa, ON

P11

Microbiological efficiency of the combinations of two carbapenems against *Klebsiella pneumoniae* carbapenemase-producing strains

EV Timoskova, DV Tapalski

Gomel State Medical University, Gomel, Belarus



P12

Waning anti-SARS-CoV2-2 plaque reduction neutralization test titers in repeat Canadian convalescent plasma donors: April-December 2020SJ Drews^{1,2}, DV Devine^{3,4}, J McManus³, E Mendoza⁵, K Manguiat⁵, R Girardin⁶, A Dupuis⁶, K McDonough^{6,7}, YCJ Lin^{8,9}, DH Evans^{8,9}, C Pambrun¹⁰, M Drebot^{5,11}, H Wood⁵¹Canadian Blood Services, Microbiology, Edmonton, AB; ²Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB; ³Canadian Blood Services, Vancouver, BC; ⁴Centre for Blood Research and Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; ⁵Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; ⁶Wadsworth Center, New York State Department of Health, Albany, NY, USA; ⁷Department of Biomedical Sciences, School of Public Health, University at Albany, Albany, NY, USA; ⁸Medical Microbiology & Immunology, University of Alberta, Edmonton, AB; ⁹Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB; ¹⁰Canadian Blood Services, Medical Affairs and Innovation, Ottawa, ON; ¹¹Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB

P13

Impact of the COVID-19 pandemic on the incidence and serotype distribution of invasive pneumococcal disease in south-central OntarioA McGeer¹, KR Barker², A Campigotto³, L Matukas⁴, D Richardson⁵, C Vermeiren⁶, R Lovinsky⁷, N Farshait⁸, A Plevneshi¹, K Hassan¹, I Martin⁹¹Sinai Health System, Toronto, ON; ²Trillium Health Partners, Mississauga, ON; ³Hospital for Sick Children, Toronto, ON; ⁴Unity Health, Toronto, ON; ⁵William Osler Health System, Brampton, ON; ⁶Shared Health Laboratories, North York, ON; ⁷Scarborough Health Network, Toronto, ON; ⁸Humber River Hospital, Toronto, ON; ⁹National Microbiology Laboratory, Winnipeg, MB

P14

Impact of an antimicrobial stewardship initiative to reduce asymptomatic bacteriuria in a tertiary hospitalMO Wong, N Makhoul, S Hosseini, K Afra
Fraser Health, Surrey, BC

P15

Development of quality indicators to evaluate appropriate empiric antimicrobial use in pediatric patientsE Black^{1,2}, H MacKinnon¹, J Comeau^{1,2}, K Timberlake³, M Science³, K Slayter^{1,2}¹Dalhousie University, Halifax, NS; ²IWK Health Centre, Halifax, NS; ³The Hospital for Sick Children, Toronto, ON

P16

Penicillin susceptibility in *Staphylococcus aureus* - An opportunity for antimicrobial stewardship?P Lagacé-Wiens^{1,2}, M Stein^{1,2}, P Pieroni¹, HJ Adam^{1,2}, CY Turenne^{1,2}, A Walkty^{1,2}, T Wuerz^{2,3}, JA Karlowsky^{1,2}¹Shared Health, Winnipeg, MB; ²University of Manitoba, Winnipeg, MB; ³Saint-Boniface Hospital, Winnipeg, MB

P17

Nosocomial SARS-CoV-2 infection in healthcare workers (HCWs): descriptive analysis of a large acute care hospital COVID-19 outbreak on cardiac unitsD Dixit^{1,2}, JM Conly^{1,3}, K Snedeker^{1,3}, N Etches^{1,3}, A Weiss¹, M Suddes¹, P Jameison^{1,3}, S Tsekrekos^{1,4}¹Alberta Health Services, Calgary, AB; ²University of Saskatchewan, Saskatoon, SK; ³University of Calgary, Calgary, AB; ⁴University of Alberta, Edmonton, AB


P18

Verification of the Vitek® 2 N391 gram-negative AST Card - Results are method-dependentP Lagacé-Wiens^{1,2}, M Stein^{1,2}, P Pieroni¹, HJ Adam^{1,2}, CY Turenne^{1,2}, A Walkty^{1,2}, JA Karlowsky^{1,2}¹Shared Health, Winnipeg, MB; ²University of Manitoba, Winnipeg, MB

P19

Evaluation of the Solana® Influenza A and B nucleic acid amplification assayP Lagacé-Wiens^{1,2}, M Stein^{1,2}, P Pieroni¹, HJ Adam^{1,2}, CY Turenne^{1,2}, A Walkty^{1,2}, JA Karlowsky^{1,2}¹Shared Health, Winnipeg, MB; ²University of Manitoba, Winnipeg, MB

P20

Stepwise implementation of an antimicrobial stewardship prospective audit and feedback intervention at a large academic centre in CanadaJZ Chen^{1,2}, C Cervera¹, SW Smith^{1,2}, D Kabbani^{1,2}, C Lau³, S Bains³, K Fong³, J Stewart³, KE Doucette^{1,2}¹Division of Infectious Diseases, University of Alberta, Edmonton, AB; ²Alberta Health Services, Edmonton, AB; ³Pharmacy Services, Alberta Health Services, Edmonton, AB

P21**SARS-CoV2 outbreak amongst physicians at a Canadian curling bonspiel: a descriptive observational study**

B Meatherall¹, S Law², C Rice², J Hu³, C Fung⁴, A Woo⁵, K Fonseca^{6,7}, A Lang⁸, J Kanji^{9,10}, K Burak^{2,11}

¹Division of Infectious Diseases, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB; ²Physician Learning Program, Continuing Medical Education and Professional Development, Cumming School of Medicine, University of Calgary, Calgary, AB; ³Medical Officer of Health, Alberta Health Services; Department of Community Health Sciences, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB; ⁴Department of Radiology and Diagnostic Imaging, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB; ⁵Division of Orthopedics, Department of Surgery, College of Medicine, University of Saskatchewan, Saskatoon, SK; ⁶Provincial Laboratory for Public Health, Alberta Precision Laboratories, Calgary, AB; ⁷Department of Microbiology, Immunology & Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB; ⁸Roy Romano Provincial Lab, Saskatchewan Health Authority, Regina, SK; ⁹Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB; ¹⁰Provincial Laboratory for Public Health, Alberta Precision Laboratories, Edmonton, AB; ¹¹Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB

P22**Verification of 2019 CLSI M100 Revised Ciprofloxacin Breakpoints for *Pseudomonas aeruginosa* using the Vitek® 2 N391 Gram-Negative AST Card**

P Lagacé-Wiens^{1,2}, M Stein^{1,2}, P Pieroni¹, HJ Adam^{1,2}, CY Turenne^{1,2}, A Walkty^{1,2}, JA Karlowsky^{1,2}

¹Shared Health, Winnipeg, MB; ²University of Manitoba, Winnipeg, MB

P23**Congenital SARS-CoV-2 infection in a pre-term neonate with viable virus from the placenta**

JV Vayalumkal¹, A Soraisham¹, A Abou-Mehrem¹, J Dunn¹, K Fonseca^{2,3}, B Berenger^{2,3}, MA Brundler³, Elaine Chan³, YCJ Lin⁴, D Evans⁴, JM Conly⁵

¹Department of Pediatrics, University of Calgary, Calgary, AB; ²Alberta Public Health Laboratory, Calgary, AB; ³Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB; ⁴Department of Medicine, University of Calgary, Calgary, AB

P24**Comparative analysis of capillary versus venous blood for serologic detection of SARS-CoV-2 antibodies by rPOC lateral flow tests**

T Pidduck, I Sekirov, M McLennan, P Levett, N Chahil, A Mak, E Carruthers, J Kustra, K Chu, F Burgess, L Willis, R Wada, R Blancaflor, M Krajden, MG Morshed

BCCDC Public Health Laboratory, Vancouver, BC

P25**Cefiderocol therapy in a Canadian urban academic centre: A new option to treat carbapenem-resistant gram-negative infections**

C Ondro¹, I Rajakumar¹, S Bourassa-Blanchette^{1,2}, A Ugarte-Torres^{1,2}, J Salmon^{1,2}

¹Alberta Health Services, Calgary, AB; ²Department of Medicine, University of Calgary, Calgary, AB

P26**Survey results from a pilot antimicrobial stewardship prospective audit and feedback in general surgery**

AJ Chan¹, M Tsang^{1,2}, BJ Langford^{3,4}, M Downing^{1,2}

¹Unity Health Toronto, Toronto, ON; ²University of Toronto, Toronto, ON; ³Public Health Ontario, Toronto, ON; ⁴Hotel Dieu Shaver Health and Rehabilitation Centre, St. Catharines, ON

P27**Associated antibiotic use for community infections in British Columbia: a review of prescribing from 2000 – 2018**

A Saatchi¹, AM Morris², DM Patrick^{3,4}, J McCormack¹, F Marra^{1,3}

¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC; ²Sinai Health System, University Health Network, and University of Toronto, Toronto, ON; ³British Columbia Centre for Disease Control, Vancouver, BC; ⁴School of Population and Public Health, University of British Columbia, Vancouver, BC

P28**The impact of a reported beta-lactam allergy on cefazolin administration in surgical prophylaxis: cefazolin is still best, but is it given?**



HL Hoang^{1,2}, KC Crick³, JZ Chen^{1,4}, SR Fryters⁵, AU Chandran⁴, AW Tse-Chang^{4,6}, DC Williams^{4,7}, TW Myroniuk³, RO Yeung³, D Campbell-Scherer³, LM Saxinger^{1,4}



¹Division of Infectious Diseases, University of Alberta, Edmonton, AB; ²Covenant Health, Edmonton, AB; ³Physician Learning Program, Edmonton, AB; ⁴Alberta Health Services, Edmonton, AB; ⁵Pharmacy Services, Alberta Health Services, Edmonton, AB; ⁶Division of Pediatric Infectious Diseases, University of Alberta, Edmonton, AB; ⁷Department of Surgery, University of Alberta, Edmonton, AB

P29**A review of surgical antibiotic prophylaxis practice in adult urology procedures: opportunities for antimicrobial stewardship collaboration**

JZ Chen^{1,2}, HL Hoang^{1,3}, KC Crick⁴, SR Fryters⁵, AU Chandran², DC Williams^{2,6}, T Myroniuk⁴, RO Yeung⁴, D Campbell-Scherer⁴, LM Saxinger¹

¹Division of Infectious Diseases, University of Alberta, Edmonton, AB; ²Alberta Health Services, Edmonton, AB; ³Covenant Health, Edmonton, AB; ⁴Physician Learning Program, Edmonton, AB; ⁵Pharmacy Services, Alberta Health Services, Edmonton, AB; ⁶Department of Surgery, University of Alberta, Edmonton, AB

**P30****Real-life experience with ceftobiprole in Canada: results from the CLEAR (Canadian Leadership on Antimicrobial Real-life usage) Registry**GG Zhanel¹, J Kosar², M Baxter¹, R Dhimi³, S Borgia⁴, N Irfan⁵, KS MacDonald¹, G Dow⁶, P Lagace-Wiens¹, M Dube⁷, M Bergevin⁸, YKeynan¹, A Lee⁹, A Walkty¹, JA Karlowsky¹¹University of Manitoba, Winnipeg, MB; ²Royal University Hospital, Saskatoon, SK; ³London Health Sciences Centre, London, ON; ⁴William Osler Health System, Brampton, ON; ⁵Hamilton Health Sciences Centre, Hamilton, ON; ⁶The Moncton Hospital, Moncton, NB; ⁷Sainte-Croix Hospital, Drummondville, QC; ⁸Cité de la Santé, Montréal, QC; ⁹Scarborough Health Network, Toronto, ON**P31****An examination of selection, timing and duration of surgical prophylaxis for vascular procedures at a major Canadian vascular surgery centre**HL Hoang^{1,2}, GB Winkelaar^{3,4}, KC Crick⁵, JZ Chen^{1,6}, SR Fryters⁷, AU Chandran⁶, DC Williams^{3,6}, TW Myroniuk⁵, RO Yeung⁵, D Campbell-Scherer⁵, LM Saxinger^{1,6}¹Division of Infectious Diseases, University of Alberta, Edmonton, AB; ²Covenant Health, Edmonton, AB; ³Department of Surgery, University of Alberta, Edmonton, AB; ⁴Northern Alberta Vascular Centre, Edmonton, AB; ⁵Physician Learning Program, Edmonton, AB; ⁶Alberta Health Services, Edmonton, AB; ⁷Pharmacy Services, Alberta Health Services, Edmonton, AB**P32****An audit of surgical antibiotic prophylaxis in orthopedic surgery with particular focus on duration of prophylaxis**SR Fryters¹, JZ Chen², AU Chandran³, HL Hoang², LM Saxinger², KC Crick⁴, TW Myroniuk⁴, DC Williams⁵, RO Yeung⁴, D Campbell-Scherer⁴, AW Tse-Chang⁶¹Pharmacy Services, Alberta Health Services, Edmonton, AB; ²Division of Infectious Diseases, University of Alberta, Edmonton, AB; ³Alberta Health Services, Edmonton, AB; ⁴Physician Learning Program, Edmonton, AB; ⁵Department of Surgery, University of Alberta, Edmonton, AB; ⁶Division of Pediatric Infectious Diseases, University of Alberta, Edmonton, AB**P33****An assessment of surgical antibiotic prophylaxis practices at a Canadian tertiary pediatric centre**AW Tse-Chang^{1,2}, KC Crick³, SR Fryters⁴, AU Chandran^{2,5}, DC Williams^{2,6}, TW Myroniuk³, RO Yeung³, D Campbell-Scherer³, LM Saxinger^{2,7}¹Division of Pediatric Infectious Diseases, University of Alberta, Edmonton, AB; ²Alberta Health Services, Edmonton, AB; ³Physician Learning Program, University of Alberta, Edmonton, AB; ⁴Pharmacy Services, Alberta Health Services, Edmonton, AB; ⁵University of Alberta, Edmonton, AB; ⁶Department of Surgery, University of Alberta, Edmonton, AB; ⁷Division of Infectious Diseases, University of Alberta, Edmonton, AB**P34****Comparison of contact precautions with routine practices for the prevention of vancomycin-resistant *Enterococci* (VRE) infections in hospitals: The secret is in the routine**H Glassman¹, LE Burnes¹, AC McFarlane^{1,2}, AU Chandran^{1,2}¹University of Alberta, Edmonton, AB; ²Royal Alexandra Hospital, Edmonton, AB**P35****What's in a number? The value of titres as routine proof of immune protection**NC Marshall^{1,2}, ANM Bailey¹, LA Thompson¹, JN Kanji^{1,2,3}, CL Charlton^{1,2}¹Division of Diagnostic & Applied Microbiology, Department of Laboratory Medicine & Pathology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB; ²Alberta Provincial Public Health Laboratory, Edmonton, AB; ³Division of Infectious Diseases, Department of Medicine & Medical Microbiology/Immunology, Edmonton, AB**P36****A case of multisystem inflammatory syndrome in adults (MIS-A): a rare manifestation of COVID-19**T King¹, J Mah², A Johnson², M Fritzler^{1,3}, B Yipp⁴, M Gillrie^{2,5}¹Department of Medicine, University of Calgary, Calgary, AB; ²Division of Infectious Diseases, Department of Medicine, University of Calgary, Calgary, AB; ³Department of Biochemistry & Molecular Biology, University of Calgary, Calgary, AB; ⁴Department of Critical Care, University of Calgary, Calgary, AB; ⁵Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB**P37****Absence of transmission of NDM and OXA-48-like Carbapenemase Genes in a long-term care facility**C Boodman¹, N Gibson², D Conrod², CY Turenne¹, D Alexander¹, D Boyd³, L Mataseje³, M Mulvey³, JA Karlowsky⁴, M Blake², J Embil¹¹University of Manitoba, Winnipeg, MB; ²Winnipeg Regional Health Authority, Winnipeg, MB; ³National Microbiology Laboratory, Winnipeg, MB; ⁴University of Manitoba, Winnipeg, MB

**P38****Sensitivity of Cobas® 68/8800 SARS-CoV-2 test using gargle specimens with two different processing methods**P Benoit¹, AC Labbé^{1,2,3}, L Lalancette⁴, S Gagnon², E Bonneau⁴, J Fafard⁵, S Beauchemin², A Jetté², S Tremblay⁴, K Filiatrault⁴, F Vancol-Fable², F Coullée^{1,2}¹Université de Montréal, Montréal, QC; ²Centre Hospitalier de l'Université de Montréal, Montréal, QC; ³Centre intégré universitaire de santé et de services sociaux de l'Est-de-l'Île-de-Montréal, Montréal, QC; ⁴Centre Hospitalier Saint-Eustache, Saint-Eustache, QC; ⁵Laboratoire de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC**P39****Evaluation of the Q Score for assessing wound swab quality in a tertiary care centre**JD Forbes¹, ST Clark¹, LM Matukas^{1,2}¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; ²St. Michael's Hospital, Unity Health Toronto, Toronto, ON**P40****Susceptibility patterns for *Enterococcus* spp. clinical isolates collected over a 14-year period**V Bugaj¹, SAN Walker^{1,2}, C Peragine²¹Leslie L. Dan Faculty of Pharmacy, University of Toronto, Toronto, ON; ²Department of Pharmacy, Sunnybrook Health Sciences Centre, Toronto, ON**P41****Maternal and fetal infection of non-typhoidal *Salmonella* during pregnancy**XX Li^{1,2}, CK Lo¹, JM Pernica³, P El-Helou¹¹Division of Infectious Diseases, McMaster University, Hamilton, ON; ²Division of Medical Microbiology, McMaster University, Hamilton, ON; ³Division of Pediatric Infectious Diseases, McMaster University, Hamilton, ON**P42****Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) Registry**GG Zhanel¹, R Dhama², M Baxter¹, J Kosar³, C Cervera⁴, N Irfan⁵, R Zvonar⁶, S Borgia⁷, JF Tessier⁸, G Dow⁹, R Ariano¹⁰, M Dube¹¹, M Savoie⁸, S Lutes¹², A Walkty¹, J Karlowsky¹¹University of Manitoba, Winnipeg, MB; ²London Health Sciences Centre, London, ON; ³Royal University Hospital, Saskatoon, SK; ⁴University of Alberta, Edmonton, AB; ⁵Hamilton Health Sciences Centre, Hamilton, ON; ⁶The Ottawa Hospital, Ottawa, ON; ⁷William Osler Health System, Brampton, ON; ⁸CIUSSS de l'Est-de-l'Île-de-Montréal, Montréal, QC; ⁹The Moncton Hospital, Moncton, NB; ¹⁰St. Boniface Hospital, Winnipeg, MB; ¹¹Sainte-Croix Hospital, Drummondville, QC; ¹²Queen Elizabeth Hospital, Charlottetown, PE**P43****Risks factors for severe outcomes in patients hospitalized with COVID-19 in a network of Canadian acute-care hospitals**R Mitchell¹, K Baekyung Choi¹, L Pelude¹, W Rudnick¹, J Brooks¹, J Comeau², JM Conly³, C Ellis⁴, J Ellison⁵, J Embil⁶, GA Evans⁷, GJ German⁸, BL Johnston⁹, J Johnstone¹⁰, KC Katz¹¹, P Kibsey¹², BE Lee¹³, MA Lefebvre^{14,15}, Y Longtin¹⁶, A McGeer¹⁰, D Mertz¹⁷, J Minion¹⁸, C Quach¹⁹, S Smith²⁰, J Srigley²¹, P Stagg²², KN Suh²³, A Wong²⁴, N Thampi²⁵, C Frenette¹⁵¹Public Health Agency of Canada, Ottawa, ON; ²IWK Health Centre, Halifax, NS; ³University of Calgary, Calgary, AB; ⁴The Moncton Hospital, Moncton, NB; ⁵Alberta Health Services, Calgary, AB; ⁶Health Sciences Centre, Winnipeg, MB; ⁷Kingston Health Sciences Centre, Kingston, ON; ⁸Queen Elizabeth Hospital, Charlottetown, PE; ⁹QEII Health Sciences Centre, Halifax, NS; ¹⁰Sinai Health, Toronto, ON; ¹¹North York General Hospital, Toronto, ON; ¹²Royal Jubilee Hospital, Victoria, BC; ¹³Stollery Children's Hospital, Edmonton, AB; ¹⁴Montréal Children's Hospital, Montréal, QC; ¹⁵McGill University Health Centre, Montréal, QC; ¹⁶SMBD-Jewish General Hospital, Montréal, QC; ¹⁷McMaster University and Hamilton Health Sciences, Hamilton, ON; ¹⁸Saskatchewan Health Authority, Regina, SK; ¹⁹CHU Sainte-Justine, Montréal, QC; ²⁰University of Alberta Hospital, Edmonton, AB; ²¹BC Women's and Children's Hospital, Vancouver, BC; ²²Western Memorial Hospital, Corner Brook, NL; ²³The Ottawa Hospital, Ottawa, ON; ²⁴Royal University Hospital, Saskatoon, SK; ²⁵Children's Hospital of Eastern Ontario, Ottawa, ON**P44****Reliability of E-gene Cycle Threshold (Ct) Values in Interpreting Duration of COVID-19 Infection**W Stokes^{1,2,3}, J Kanji^{1,2,3}, J Hu^{4,5}, N Zelyas^{2,6}, B Berenger^{7,8}¹Alberta Public Health Laboratory, Alberta Precision Laboratories, Edmonton, AB; ²Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB; ³Division of Infectious Diseases, Department of Medicine, Edmonton, AB; ⁴Department of Community Health Sciences, University of Calgary, Calgary, AB; ⁵Public Health, Alberta Health Services, Calgary, AB; ⁶Alberta Public Health Laboratory, Alberta Precision Laboratories, Edmonton, AB; ⁷Alberta Public Health Laboratory, Alberta Precision Laboratories, Calgary, AB; ⁸Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB**P45****Susceptibility of *Pseudomonas aeruginosa* to empiric therapy and alternative β -lactam antimicrobials in intensive care unit patients with respiratory tract infections in Canadian centers: SMART surveillance (2016-2019)**R ElAli¹, M Gonzalez², C Ghakis¹, E O'Callaghan¹¹Merck Canada Inc., Kirkland, QC; ²MSD, Madrid, Spain

**P46**

Nasopharyngeal expression of Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Serine Protease 2 (TMPRSS2) in children compared to adults within family clusters exposed to COVID-19
M Rubayet Hasan^{1,2}, M Naseer Ahmad¹, A Al Hashemi¹, P Tang^{1,2}

¹Sidra Medicine, Doha, Qatar; ²Weill Cornell Medicine - Qatar, Doha, Qatar

P47

The association of frailty and outcomes among hospitalized COVID-19 patients in Toronto

A Shigayeva¹, MK Andrew², K Katz^{3,4}, A Simor^{3,5}, D Melady¹, E Coomes^{3,6}, B Coleman^{1,3}, J Kwong^{3,7}, A McGeer^{1,3}, C Kandel^{1,3}

¹Sinai Health, Toronto, ON; ²Dalhousie University, Halifax, NS; ³University of Toronto, Toronto, ON; ⁴North York General Hospital, Toronto, ON; ⁵Sunnybrook Hospital, Toronto, ON; ⁶University Health Network, Toronto, ON; ⁷Public Health Ontario, Toronto, ON

P48

Real-life experience with IV fosfomycin in Canada: results from the CLEAR (Canadian Leadership on Antimicrobial Real-life usage) Registry

GG Zhanel¹, A Lee², M Baxter¹, N Irfan³, C Rotstein⁴, G Girouard⁵, M Dube⁶, A Walkty¹, JA Karlowsky¹

¹University of Manitoba, Winnipeg, MB; ²Scarborough Health Network, Toronto, ON; ³Hamilton Health Sciences Centre, Hamilton, ON; ⁴University Health Network, Toronto, ON; ⁵Centre Hospitalier Universitaire Dr-Georges-L.-Dumont, Moncton, NB; ⁶Sainte-Croix Hospital, Drummondville, QC

P49

Antimicrobial resistance trends of *Staphylococcus aureus* isolates collected from patients over 14 years

D Bedi¹, SAN Walker¹, C Peragine²

¹Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON; ²Department of Pharmacy, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto, ON

P50

Emergency department visits and readmission rates of patients discharged on OPAT: A retrospective observational study to identify predictors

JL Martinez-Cajas¹, S McKenna², B Alvarado-Llano¹, E Wilson¹, K Leifso¹, S Perez-Patrigeon¹, GA Evans¹

¹Queen's University, Kingston, ON; ²Kingston Health Sciences Centre, Kingston, ON

P51

Prescribing pattern of restricted antimicrobials at a quaternary care academic hospital

RJ LeBlanc¹, D Kabbani², SW Smith², KE Doucette², C Lau³, S Bains³, K Fong³, J Stewart³, JZ Chen²

¹University of British Columbia, Victoria, BC; ²University of Alberta, Edmonton, AB; ³Alberta Health Services, Edmonton, AB

P52

A quality audit of surgical antibiotic prophylaxis timing, redosing, and post-operative dosing practices in 5 hospital sites: The devil is in the details

LM Saxinger^{1,2}, DC William^{2,3}, KC Crick⁴, JZ Chen^{1,2}, HL Hoang^{1,5}, SR Fryters⁶, AU Chandran², TW Myroniuk⁴, RO Yeung⁴, D Campbell-Scherer⁴

¹Division of Infectious Diseases, University of Alberta, Edmonton, AB; ²Alberta Health Services, Edmonton, AB; ³Department of Surgery, University of Alberta, Edmonton, AB; ⁴Physician Learning Program, Edmonton, AB; ⁵Covenant Health, Edmonton, AB; ⁶Pharmacy Services, Alberta Health Services, Edmonton, AB

P53

Targeted plasma metabolomics method for the diagnosis of acute SARS-CoV-2

AT Le, M Wu, NA Phillips, PS Rajpurkar, M Sibai, CH Huang, MK Sahoo, J Mak, R Bowen, TM Cowan, BA Pinsky, CA Hogan

Stanford University, Palo Alto, CA, USA

P54

Lineage distributions of SARS-CoV-2 during the second wave in British Columbia

K Kamelian^{1,2}, S Russell¹, H Sbihi^{1,3}, KA Macdonald^{1,4}, D Fornika¹, T Lee¹, R Hickman¹, J Tyson¹, R Azana¹, C Ng¹, L Janz¹, L Hoang^{1,2}, N Prystajecy^{1,2}



¹British Columbia Centre for Disease Control, Vancouver, BC; ²Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; ³School of Population and Public Health, University of British Columbia, Vancouver, BC; ⁴National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

P55

Assessment of fungal ITS PCR performance in formalin-fixed paraffin-embedded tissues

ST Clark¹, YCW Yau^{1,2}, A Campigotto^{1,2}, SE Richardson^{1,2}, F Gharabaghi², M Tadros^{1,2}

¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; ²Department of Pediatric Laboratory Medicine, Division of Microbiology, The Hospital for Sick Children, Toronto, ON



P56

Comparative genomics analysis of an IncR plasmid encoding blaNDM-1 from *Enterobacter hormaechei* involved in outbreak in QuebecF Doualla-Bell¹, DA Boyd², D Roy³, K Yousfi^{1,4}, I Bernaquez¹, S Wong¹, P Savard⁵, S Bekal^{1,4}¹Laboratoire de Santé Publique du Québec, Institute National de Santé Publique du Québec, Ste Anne de Bellevue, Québec; ²Division of Enteric Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; ³Laboratoire de Santé Publique du Québec, Institute National de Santé Publique du Québec, Ste Anne de Bellevue, QC; ⁴Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, Montréal, QC; ⁵Département clinique de médecine des laboratoires OPTILAB-CHUM, Université de Montréal, Montréal, QC

P57

***Yokenella regensburgei* infection in an immunocompetent host**

FH Al Mutawa

London Health Science Center, Pathology and Laboratory Medicine, London, ON; Department of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry Western University, London, ON

P58

Performance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodiesI Sekirov^{1,2}, M Petric^{1,2}, E Carruthers¹, D Lawrence¹, N Chahil¹, P Levett^{1,2}, H Wood³, R Lindsay³, M Drebot³, M Krajdien^{1,2}, MG Morshed^{1,2}¹British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, BC; ²Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; ³National Microbiology Laboratory, Winnipeg, MB

P59

Necrotic myositis in an immunocompetent patient with persistent *Bacillus cereus* bacteremia and acute liver failure: A case report

A Cvetkovic, V Mokashi, K Woodward

McMaster University, Hamilton, ON

P60

How has antimicrobial use changed during the COVID-19 pandemic? A look at community antimicrobial use in Canada

G Smith, B Knight, D Greydanus, J Shurgold, J Brooks, D Gravel Tropper

Canadian Antimicrobial Resistance Surveillance System, Public Health Agency of Canada, Ottawa, ON

P61

Isolating *Candida auris* at Humber River Hospital: A comparative evaluation of media to develop a screening protocol for an emerging pathogen

C Morris, J Widla, J McLay, W Dubinski

Humber River Hospital, Toronto, ON

P62

WITHDRAWN

P63

Community antibiotic use at the population level during the SARS-CoV2 pandemic in British Columbia, CanadaAA Mamun¹, A Saatchi², M Xie¹, H Lishman³, E Blondel-Hill⁴, F Marra², DM Patrick^{1,3}¹British Columbia Centre for Disease Control, Vancouver, BC; ²Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC; ³School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC; ⁴Interior Health Authority, Kelowna, BC



P64


Prospective audit and feedback (PAF) in level II neonatal intensive care units (NICU) - Is it worth it?K Alsager¹, K Mponponsuo¹, G Kerkerian¹, A Krishnan², D Dersch-Mills², J Vayalumkal³, C Constantinescu³¹University of Calgary, Calgary, AB; ²Pharmacy Services, Alberta Health Services, Calgary, AB; ³Section of Infectious Diseases, Department of Pediatrics, University of Calgary, Calgary, AB


P65

Validation of the triplex real-time RT-PCR assay for detection of Chikungunya, Dengue, and Zika virusesB Hon¹, E Grandbois¹, MK Lee¹, N Chahil¹, MG Morshed^{1,2}¹BC Centre for Disease Control - Public Health Laboratory, Vancouver, BC; ²University of British Columbia, Vancouver, BC

P66

Viral co-circulation during the COVID-19 pandemic: Broad respiratory testing to inform diagnostic stewardshipNC Marshall^{1,2}, RM Kariyawasam^{1,2}, N Zelyas^{1,2}, MA Diggle^{1,2}¹Division of Diagnostic & Applied Microbiology, Department of Laboratory Medicine & Pathology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB; ²Alberta Precision Laboratories - Public Health, Edmonton, AB

**P67****The impact of ID consultation in patients with *Enterococcus* species bloodstream infection**BE Kula¹, TC Dingle², JZ Chen¹¹University of Alberta, Edmonton, AB; ²Alberta Precision Laboratories, Edmonton, AB**P68****Comparison of the BD Phoenix CPO Detect Test and the NG-Test® CARBA-5 lateral flow assay for the detection of carbapenemase-producing organisms**L Li^{1,2}, M Sidhu³, L Kishi³, T Vegdani³, G Arumugam³, M Hantid³, J Speakman³, M Charles^{1,2}¹Division of Medical Microbiology and Infection Prevention and Control, Vancouver General Hospital, Vancouver, BC; ²Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; ³Provincial Health Services Authority, Vancouver, BC**P69****Performance of three different screening media for the detection of carbapenemase-producing organisms**L Li^{1,2}, M Sidhu³, L Kishi³, T Vegdani³, G Arumugam³, M Hantid³, J Speakman³, M Charles^{1,2}¹Division of Medical Microbiology and Infection Prevention and Control, Vancouver General Hospital, Vancouver, BC; ²Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; ³Provincial Health Services Authority, Vancouver, BC**P70****Comparison of two commercial broth microdilution methods for testing susceptibility to colistin in multi-drug resistant gram-negative organisms**L Li^{1,2}, J Grant^{1,2}, M Sidhu³, J Hsu³, J Hughes³, M Charles^{1,2}¹Division of Medical Microbiology and Infection Prevention and Control, Vancouver General Hospital, Vancouver, BC; ²Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; ³Provincial Health Services Authority, Vancouver, BC**P71****An audit of surgical antibiotic prophylaxis in obstetrical/gynecological surgery**SR Fryters¹, JZ Chen², AU Chandran³, HL Hoang², LM Saxinger², KC Crick⁴, TW Myroniuk⁴, DC Williams⁵, RO Yeung⁴, D Campbell-Scherer⁴¹Pharmacy Services, Alberta Health Services, Edmonton, AB; ²Division of Infectious Diseases, University of Alberta, Edmonton, AB; ³Alberta Health Services, Edmonton, AB; ⁴Physician Learning Program, Edmonton, AB; ⁵Department of Surgery, University of Alberta, Edmonton, AB**P72****Using Propidium monoazide in Real-Time quantitative PCR to distinguish viable versus non-viable enteric viruses in water samples**
MB Glier¹, R Han², S Man³, C Tchao¹, F Tsang¹, N Prystajec^{1,2}¹Public Health Laboratory, BC Centre for Disease Control, Vancouver, BC; ²Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; ³LifeLabs, BC**P73****Validation of gargle samples on the point-of-care cobas Liat for the detection of SARS-CoV-2**J Fafard¹, F Tourangeau², J Dumaresq^{3,4}, F Doualla-Bell¹, S Fournier², L Josée Caron², S Beauchemin^{5,6}, AC Labbé^{5,6,7}¹Laboratoire de Santé Publique du Québec, INSPQ, Ste-Anne-de-Bellevue, QC; ²CISSS du Bas-Saint-Laurent, Rimouski, QC; ³Département de microbiologie-infectiologie et immunologie, Faculté de médecine, Université Laval, Québec, QC; ⁴CISSS de Chaudière-Appalaches, Lévis, QC; ⁵CIUSSS de l'Est-de-l'Île-de-Montréal, Montréal, QC; ⁶CHUM, Montréal, QC; ⁷Département de microbiologie, infectiologie et immunologie, Faculté de médecine, Université de Montréal, Montréal, QC**P74****Cohort study of children hospitalized with COVID-19 infection**M Barton¹, A Trajtman², R Ulloa-Gutierrez³, H Brenes-Chacon³, A Yock-Corralles³, G Ivankovich-Escoto³, A Soriano-Fallas³, M Hernandez-de Mezerville³, A Bitnun⁴, S Morris⁴, T El Tal⁴, EA Yeh⁴, P Gill⁴, R Laxer⁴, A Nateghian⁵, B Haghghi Ask⁵, A Manafif⁵, J Papenburg⁶, MA Lefebvre⁶, S Cooke⁷, T Dewan⁷, L Restivo⁷, I Viel-Thériault⁸, R Dwillow², J Bullard², A Roberts⁹, M Sadarangani⁹, NMA Le Saux¹⁰, J Bowes¹⁰, J Wong¹¹, R Purewal¹², J Lautermilch¹², K Leifso¹³, C Foo¹⁴, LA Newhook¹⁴, A Bayliss¹⁵, JL Robinson¹⁶¹Western University, London, ON; ²University of Manitoba, Winnipeg, MB; ³Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera", San Jose, Costa Rica; ⁴University of Toronto, Toronto, ON; ⁵Iran University of Medical Sciences, Tehran, Iran; ⁶McGill University, Montréal, QC; ⁷University of Calgary, Calgary, AB; ⁸Laval University, Québec, QC; ⁹University of British Columbia, Vancouver, BC; ¹⁰University of Ottawa, Ottawa, ON; ¹¹McMaster University, Hamilton, ON; ¹²University of Saskatchewan, Saskatoon, SK; ¹³Queen's University, Kingston, ON; ¹⁴Memorial University, St John's, NL; ¹⁵Credit Valley Hospital, Mississauga, ON; ¹⁶University of Alberta, Edmonton, AB



P75

Evaluation of the Allplex™ 2019-nCoV assay for the detection of SARS-CoV-2 in a variety of clinical matrices

ST Clark¹, B Hazlett², S Isabel¹, A Aquino², Q Liu², TT Mazzulli^{1,2}, SM Poutanen^{1,2,3}

¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; ²Department of Microbiology, University Health Network/Sinai Health System, Toronto, ON; ³Department of Medicine, University of Toronto, Toronto, ON

P76

Analysis of the performance of water gargle samples for SARS-CoV-2 detection by RT-PCR in a pediatric population

E Vallières^{1,2}, J Fafard³, AC Labbé^{2,4,5}, M Bergevin^{2,6}, Z Laghdir¹, S Beauchemin^{4,5}, M Desforges^{1,2}

¹CHU Sainte-Justine, Montréal, QC; ²Département de microbiologie, infectiologie et immunologie, Faculté de médecine, Université de Montréal, Montréal, QC; ³Laboratoire de Santé Publique du Québec, INSPQ, Ste-Anne-de-Bellevue, QC; ⁴CIUSSS de l'Est-de-l'Île-de-Montréal, Montréal, QC; ⁵CHUM, Montréal, QC; ⁶CISSS de Laval, Laval, QC

P77

Persistent *Pandoraea sporum* bacteremia in a patient with extensive burns: a case report

V Weaver¹, M Clifford-Rashotte¹, V Lavergne², T Wong²

¹University of British Columbia, Vancouver, BC;

²Vancouver General Hospital, Vancouver, BC

P78

Validation of the EuroImmuno Anti-SARS-CoV-2 ELISA assay for detection of IgG and IgA antibodies in human breast milk

S Anwer¹, S Ismail², Y Yau^{2,3}, S Unger^{2,4}, D O'Connor^{2,3,4}, SM Poutanen^{1,2}

¹University Health Network/Sinai Health Department of Microbiology, Toronto, ON; ²University of Toronto, Toronto, ON; ³The Hospital for Sick Children, Toronto, ON; ⁴Mount Sinai Hospital, Toronto, ON

P79

Ct as an indicator of SARS-CoV-2 WGS success

KA Macdonald^{1,2}, C Fjell², H Sbihi^{2,3}, D Fornika², L Hoang^{2,4}, N Prystajecy^{2,4}

¹National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; ²BC Centre for Disease Control Public Health Laboratory, Provincial Health Services Agency, Vancouver, BC; ³School of Population and Public Health, The University of British Columbia, Vancouver, BC; ⁴Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC

P80

Sex-based differences in asexual organisms? Differences in the prevalence of antibiotic-resistance and multidrug-resistance in a retrospective sample of bacterial isolates collected from acute care male and female inpatients

D Peragine¹, C Peragine²

¹Department of Psychology, University of Toronto, Toronto, ON; ²Department of Pharmacy, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto, ON

P81

Expediting QC for COVID WGS analysis via Dashboards

KA MacDonald^{1,2}, D Fornika², C Fjell², H Sbihi^{2,3}, L Hoang^{2,4}, N Prystajecy^{2,4}

¹National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; ²BC Centre for Disease Control Public Health Laboratory, Provincial Health Services Agency, Vancouver, BC; ³School of Population and Public Health, The University of British Columbia, Vancouver, BC; ⁴Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC

P82

The frequency of Carbapenemase-producing Enterobacterales during COVID-19

S Anwer¹, B Hazlett¹, M Kisooson¹, A McGeer^{1,2}, TT Mazzulli^{1,2}, SM Poutanen^{1,2}


¹University Health Network/Sinai Health Department of Microbiology, Toronto, ON; ²University of Toronto, Toronto, ON

P83

Realization of theoretical savings following implementation of bioMerieux's VITEK® MS for rapid microbial identification in patients with blood stream infections

GL Carr, W Gouliquer, A Skillen, D Welbourne, G Gamble

Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON



STUDENT E-POSTERS

On Demand starting Sunday, April 25
Poster Hall



Live Interaction, Poster Presenters at Posters

*participation by presenters may vary

Monday, April 26	16:00 – 18:00 EDT
Wednesday, April 28	15:45 – 17:45 EDT
Thursday, April 29	16:15 – 18:00 EDT
Friday, April 30	10:00 – 12:00 EDT

SP01

Examination of the horizontal gene transfer dynamics of an integrative and conjugative element in *Histophilus somni*

MM Farghaly¹, MM Nazari¹, MF Hynes², S Checkley¹, N Rawlyk³, K Liljebjelke¹

¹Department of Ecosystem and Public Health, Faculty of Veterinary Medicine, University of Calgary, Calgary, AB; ²Department of Biological Science, Faculty of Science, Calgary, AB; ³Vaccine and Infectious Disease Organization International Vaccine Centre, Saskatoon, SK

SP02

Antiviral use among Canadian children hospitalized for influenza, 2010-2019

K Mehta¹, S Morris², JA Bettinger³, W Vaudry⁴, T Jadavji⁵, SA Halperin⁶, C Bancej⁷, M Sadarangani^{3,8}, N Dendukuri^{1,9}, J Papenburg^{1,9,10,11}

¹Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, QC; ²Division of Pediatric Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON; ³Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, BC; ⁴Division of Pediatric Infectious Diseases, Department of Paediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, AB; ⁵Section of Infectious Diseases, Department of Paediatrics, Alberta Children's Hospital, University of Calgary, Calgary, AB; ⁶Canadian Center for Vaccinology, IWK Health Center, Dalhousie University, Halifax, NS; ⁷Center for Immunization & Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON; ⁸Department of Pediatrics, University of British Columbia, Vancouver, BC; ⁹Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montréal, QC; ¹⁰Division of Pediatric Infectious Diseases, Department of Pediatrics, Montréal Children's Hospital, McGill University Health Centre, Montréal, QC; ¹¹Division of Microbiology, Department of Clinical Laboratory Medicine, McGill University Health Centre, Montréal, QC

SP03

Jamestown Canyon and snowshoe hare virus seroprevalence in New Brunswick

J Mincer¹, S Materniak², K Dimitrova³, H Wood³, M Iranpour³, A Dibernardo³, C Loomer³, MA Drebot³, R Lindsay³, D Webster^{1,2,4}

¹Dalhousie Medicine New Brunswick, Dalhousie University, Saint John, NB; ²Horizon Health Network, Saint John, NB; ³National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; ⁴Division of Infectious Diseases, Saint John Regional Hospital, Saint John, NB

SP04

Evaluation of the identification of *Staphylococcus pseudintermedius* from human wound cultures

HL Bibby¹, KL Brown^{1,2}

¹Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB; ²Department of Medicine, University of Calgary, Calgary, AB

SP05

**Getting to the heart of the matter:
A case of *Bartonella quintana* endocarditis
with serological cross-reactivity to
*Coxiella burnetii***H Glassman¹, SC Houston¹, A Alrohim¹,
P Dobrowolski¹, M Oosthuizen², JZ Chen¹¹University of Alberta, Edmonton, AB;
²Tamarack Medical Clinic, Cranbrook, BC

SP06

**The difference between age- and weight-
based approach to determine adequate
volume of blood culture volume drawn
from pediatric patients**EYH Yeung^{1,2}, NMA Le Saux³¹University of Ottawa, Ottawa, ON; ²Eastern Ontario
Regional Laboratory Association, Ottawa, ON;
³Children's Hospital of Eastern Ontario, Ottawa, ON

SP07

**Invasive mould disease in fatal COVID-19:
A systematic review of autopsies**BE Kula¹, CJ Clancy², M Hong Nguyen²,
IS Schwartz¹¹University of Alberta, Edmonton, AB;
²University of Pittsburgh, Pittsburgh, PA, USA

SP08

**Risk factors and protective measures for
healthcare worker infection during highly
infectious viral respiratory epidemics: a
systematic review and meta-analysis**C Tian¹, O Lovrics², A Vaisman³, K Chin⁴,
G Tomlinson⁵, Y Lee⁶, M Englesakis⁷,
M Parotto^{4,8}, M Singh^{4,8}¹Faculty of Medicine, University of Toronto, Toronto, ON;
²Faculty of Medicine, McMaster University, Hamilton, ON;
³Infection Prevention and Control, University Health Network,
Toronto, ON; ⁴Department of Anesthesia and Pain
Management, University Health Network, Toronto, ON;
⁵Department of Medicine, University Health Network,
Toronto, ON; ⁶Division of General Surgery, McMaster
University, Hamilton, ON; ⁷Information Specialist, Library
& Information Services, University Health Network,
Toronto, ON; ⁸Department of Anesthesia and Pain
Management, Women's College Hospital, Toronto, ON

SP09

**Recovering influenza genomes from
wild bird habitats for better avian
flu surveillance**KS Kuchinski¹, J Duan¹, M Coombe^{1,2},
C Himsworth^{1,2}, W Hsiao¹, N Prystajek^{1,3}¹University of British Columbia, Vancouver, BC;
²BC Ministry of Agriculture, Abbotsford, BC;
³BC Centre for Disease Control, Vancouver, BC

SP10

**A nine-month evaluation of a prenatal
universal screening program for Hepatitis
C (HCV) in Alberta, Canada**LA Thompson¹, CL Charlton^{1,2}¹Department of Laboratory Medicine and Pathology,
University of Alberta, Edmonton, AB; ²Alberta Precision
Laboratories, AHS-Edmonton, Edmonton, AB

SP11

**Evaluating the efficacy of the DMC40
defined microbial community on
Clostridioides difficile infection**KS Douchant^{1,2}, M Guzman¹, S Mei He¹,
C Noordhof¹, S Vanner^{1,2}, G Gloor³,
E Allen-Vercoe⁴, E Petrofi^{1,2}, PM Sheth^{1,2,5}¹Gastrointestinal Disease Research Unit (GIDRU), Queen's
University, Kingston, ON; ²Department of Biomedical and
Molecular Sciences, Queen's University, Kingston, ON;
³Department of Biochemistry, University of Western
Ontario, London, ON; ⁴Department of Molecular and
Cellular Biology, University of Guelph, Guelph, ON;
⁵Division of Microbiology, Kingston Health Sciences
Centre, Kingston, ON



SP12

**Clinical characterization of string-test
positive *Klebsiella pneumoniae* invasive
disease compared to string-test negative
K. pneumoniae invasive disease controls**IF McNamara^{1,2}, KR Barker³, B Hazlett¹,
TT Mazzulli^{1,4}, SM Poutanen^{1,4}¹University Health Network/Sinai Health System, Toronto, ON;
²University of Utah School of Medicine, SLC, Utah, USA;
³Trillium Health Partners, Mississauga, ON;
⁴University of Toronto, Toronto, ON

SP13

**Challenges of pediatric prospective
audit and feedback (PAF) during the
COVID-19 pandemic**K Alsager¹, D Dersch-Mills², J Vayalumkal^{3,4},
C Constantinescu⁵¹University of Calgary, Calgary, AB; ²Pharmacy Services,
Alberta Health Services, Calgary, AB; ³Section of Infectious
Diseases, Department of Pediatrics, University of Calgary,
Calgary, AB; ⁴Infection Prevention and Control, Alberta
Health Services, Calgary, AB; ⁵Pediatric Infectious Disease,
Clinical Assistant Professor, University of Calgary,
Calgary, AB

SP14

**Impact of compliance with inpatient
antibiotic audit and feedback on patient
and economic outcomes**S London¹, G McDonald², P Daley¹¹Memorial University of Newfoundland, St. John's, NL;
²Eastern Health, St. John's, NL

SP15**A retrospective cohort comparison of outpatient antibiotic use for seniors, across British Columbia & Ontario, from 2000 to 2018**

A Saatchi¹, J Reid², M Povitz³, S Shariff², M Silverman⁴, AM Morris⁵, DM Patrick^{6,7}, F Marra^{1,6}

¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC; ²Institute for Clinical Evaluative Sciences, Western University, London, ON; ³Department of Medicine, University of Calgary, Calgary, AB; ⁴Faculty of Medicine, University of Western Ontario, London, ON; ⁵Sinai Health System, University Health Network, and University of Toronto, Toronto, ON; ⁶British Columbia Centre for Disease Control, Vancouver, BC; ⁷School of Population and Public Health, University of British Columbia, Vancouver, BC

SP16**Extensive stomatitis caused by herpes simplex virus 1 in a small cell lung cancer patient undergoing chemoradiotherapy: a case report and literature review**

CKL Lo¹, AE Sumner², CKF Lo³, S Haider¹

¹Division of Infectious Diseases, Department of Medicine, McMaster University, Hamilton, ON; ²Department of Medicine, Queen's University, Kingston, ON; ³Department of Medicine, University of British Columbia, Vancouver, BC

SP17**Evaluation of human antibodies of the immunoglobulin class A and G against SARS-CoV-2 in serum: A provincial public health laboratory experience**

L Gilbert^{1,2}, R Needle^{1,2}, G Zahariadis^{1,3}, Y Yu^{1,3}, H Dalton-Kenny¹, RS Russell², PP Wang^{2,4}, C Donovan^{2,5}, S Hookey¹, L Jiao^{1,3}

¹Newfoundland and Labrador Public Health Microbiology Laboratory, Department of Laboratory Medicine, Eastern Health, St. John's, NL; ²Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL; ³Discipline of Laboratory Medicine, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL; ⁴Dalla Lana School of Public Health, University of Toronto, Toronto, ON; ⁵Eastern Health, St. John's, NL

SP18**Antibiotic usage in a Neonatal Intensive Care Unit (NICU) before and after the introduction of an antibiotic stewardship intervention**

M Hirtle-Lewis, R Chafe, N Bridger, J Emberley, C Foo

Janeway Children's Health and Rehabilitation Centre, St John's, NL

SP19**Are we over-reacting to cutaneous diphtheria? A 10-year review of public health investigations and diphtheria toxin testing across Alberta**

NC Marshall^{1,2}, M Baxi³, C MacDonald^{1,2}, C Sikora⁴, GJ Tyrrell^{1,2}

¹Division of Diagnostic & Applied Microbiology, Department of Laboratory Medicine & Pathology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB; ²Alberta Provincial Public Health Laboratory, Edmonton, AB; ³Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB; ⁴Alberta Health Services, AB

SP20**Exploring next-generation sequencing limits of detection for antimicrobial resistance genes in genomes and metagenomic samples**


AM Rooney^{1,2}, AR Raphenya³, RG Melano^{1,4}, DR MacFadden⁵, N Yee², AG McArthur³, PHH Schneeberger⁶, B Coburn^{1,2}

¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; ²Toronto General Research Institute, University Health Network, Toronto, ON; ³D Braley Centre for Antibiotic Discovery, M.G. DeGroot Institute for Infectious Disease Research, and the Department of Biochemistry and Biomedical Science, McMaster University, Hamilton, ON; ⁴Public Health Ontario Laboratory, Toronto, ON; ⁵Ottawa Hospital Research Institute, Ottawa, ON; ⁶Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland

SP21**Dimensions of poverty as risk factors for antimicrobial resistant organisms in Canada: A structured narrative review**

T King¹, R Schindler^{1,2}, S Chavda¹, JM Conly^{1,3,4,5}

¹Department of Medicine, University of Calgary, Calgary, AB; ²Provincial Population and Public Health, Alberta Health Services, Calgary, AB; ³Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB; ⁴O'Brien Institute for Public Health, University of Calgary, Calgary, AB; ⁵Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB



SP22

Cost-effectiveness analysis of the BioFire FilmArray Blood Culture Identification (BCID) panel molecular rapid diagnostic test compared to conventional methods for identification of *Escherichia coli* bloodstream infectionsK Mponponso¹, J Leal^{2,3,4,5}, E Spackman^{1,5},
R Somayaji^{1,2,3,5,6}, D Gregson^{1,6,7,8},
E Rennert-May^{1,2,3,5,6}¹Department of Medicine, University of Calgary, Calgary, AB; ²Department of Community Health Sciences, University of Calgary, Calgary, AB; ³Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB; ⁴Infection Prevention and Control, Alberta Health Services, Calgary, AB; ⁵O'Brien Institute for Public Health, University of Calgary and Alberta Health Services, Calgary, AB; ⁶Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB; ⁷Department of Pathology & Laboratory Medicine, University of Calgary, Calgary, AB; ⁸Alberta Precision Laboratories, University of Calgary, Calgary, AB

SP23

Management and outcome of febrile neutropenia in admitted presumed immunocompetent patients with suspected viral illnessE Morin¹, C Corriveau-Bourque², J Foulds³¹Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Alberta, Edmonton, AB; ²Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alberta, Edmonton, AB; ³Division of Pediatric Hospital Medicine, Department of Pediatrics, University of Alberta, Edmonton, AB

SP24

Assays to measure the impact of previous coronavirus infection on the immune response generated from SARS-CoV-2 infection and vaccinationFF Li¹, A Liu², E Gibbs³, G Tanunliong⁴, J Duan^{1,4},
N Prystajec^{1,4}, M Krajden^{1,4}, MG Morshed^{1,4},
S Gantt⁵, N Cashman³, I Sekirov^{1,4}, A Jassem^{1,4}¹Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; ²Experimental Medicine, University of British Columbia, Vancouver, BC; ³Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC; ⁴BC Centre for Disease Control, Vancouver, BC; ⁵Microbiology, Infectious Diseases and Immunology, University of Montréal, Montréal, QC

SP25

Endocarditis due to *Bartonella quintana*, the etiologic agent of trench fever, among four individuals linked to the same homeless shelterC Boodman, T Wuerz, P Lagacé-Wiens
University of Manitoba, Winnipeg, MB

SP26

The genomic epidemiology of Carbapenemase-Producing Enterobacterales (CPE) at a healthcare facility in Toronto, Ontario, CanadaA Jamal¹, L Mataseje², V Williams³, J Leis³, N Tjiet⁴,
S Zittermann⁴, R Melano⁴, M Mulvey⁵, K Katz³,
V Allen⁴, A McGeer^{1,6}¹University of Toronto, Toronto, ON; ²National Microbiology Laboratory, Winnipeg, MB; ³Sunnybrook Health Sciences Centre, Toronto, ON; ⁴Public Health Ontario Laboratory, Toronto, ON; ⁵National Microbiology Laboratory, Toronto, ON; ⁶Sinai Health System, Toronto, ON

SP27

An imperative of flu vaccination: A systematic review of the clinical characteristics of influenza-COVID-19 co-infectionK Varshney^{1,2,3}, R Kyada³, J Adalbert^{3,4}¹Vancouver Coastal Health, Vancouver, BC; ²School of Medicine, Deakin University, Geelong, VIC, Australia; ³College of Population Health, Thomas Jefferson University, Philadelphia, PA, USA; ⁴Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA

SP28

A dramatic shift in the nasal microbiota of individuals infected with SARS-CoV-2E Moslinger^{1,2}, K Tozer^{1,3}, K Douchant^{1,4},
C Nordhoff^{1,2}, SM He^{1,2}, H Wong⁵, P Sheth^{1,2,3,5}¹Gastrointestinal Disease Research Unit (GIDRU), Department of Medicine, Queen's University, Kingston, ON; ²Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON; ³Faculty of Health Sciences, Queen's University, Kingston, ON; ⁴Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON; ⁵Division of Microbiology, Kingston Health Sciences Centre, Kingston, ON

SP29

Empiric antimicrobial prescribing, microbiology, and antibiotic stewardship needs in early breast cancer patients in the emergency departmentV Bugaj¹, M Guirguis², C DeAngelis^{1,3,4}, C Peragine³¹Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON; ²Faculty of Pharmacy, University of Waterloo, Waterloo, ON; ³Department of Pharmacy, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto, ON; ⁴Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON

SP30

Impact of automated WASPLab incubation on plate contamination and turnaround times for cerebrospinal fluidsXX Li^{1,2}, M Gaskin³, C Main^{1,2,3}¹Division of Medical Microbiology, McMaster University, Hamilton, ON; ²Division of Infectious Diseases, McMaster University, Hamilton, ON; ³Hamilton Regional Laboratory Medicine Program, Hamilton, ON

SP31**COVID-19 Associated Pulmonary Aspergillosis (CAPA) in critically ill patients: A systematic review**RM Kariyawasam^{1,2}, TC Dingle^{1,2}, W Sligl^{3,4}, BE Kula³, IS Schwartz³¹Division of Diagnostic & Applied Microbiology, Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, AB; ²Alberta Precision Laboratories-Public Health, Edmonton, AB; ³Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB; ⁴Department of Critical Care Medicine, University of Alberta, Edmonton, AB**SP32****Comparative analysis of SARS-CoV-2 diagnosis specificity and sensitivity using three sampling methods by quantitative PCR and droplet digital PCR**E Collins^{1,2}, K Shir-Mohammadi¹, JJ Jia¹, HC Birnboim³, C Cooper^{1,2}, MA Langlois¹¹University of Ottawa, Ottawa, ON; ²Ottawa Hospital Research Institute, Ottawa, ON; ³deltaDNA Biosciences Inc, Toronto, ON**SP33****Community acquired MRSA pericarditis in a pregnant female**



O Mourad, D Koh, P El-Helou

McMaster University, Hamilton, ON

SP34**In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to Lefamulin, a new Pleuromutilin**RM Taylor¹, JA Karlowsky^{1,2}, MR Baxter¹, HJ Adam^{1,2}, A Walkty^{1,2}, P Lagacé-Wiens^{1,2}, L Mandell³, GG Zhanel¹¹Max Rady College of Medicine, University of Manitoba, Winnipeg, MB; ²Shared Health Manitoba, Winnipeg, MB; ³University of Toronto, Toronto, ON**SP35****Atypical diagnosis of typical HUS with off-site molecular stool testing**P Gregory¹, E MacAdam¹, G Patriquin^{1,2}¹Dalhousie University, Halifax, NS; ²Nova Scotia Health, Halifax, NS**SP36****Comparative evaluation of four vaporized hydrogen peroxide-based systems to decontaminate N95 respirators**ST Clark¹, H Ng², G Wu², D Jain³, R Kandel^{1,4}, TT Mazzulli^{1,2}¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; ²Department of Microbiology, University Health Network/Sinai Health System, Toronto, ON; ³Medical Engineering, University Health Network, Toronto, ON; ⁴Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON**SP37****Clinical characteristics, management and outcomes of splenic abscesses**

R Mangat, J Gray, T Louie

University of Rochester Medical Center, Rochester, NY, USA

SP38**Prevention of COVID-19 in internally displaced persons camps in Eastern Democratic Republic of the Congo: a mixed-methods study**QN Mian¹, KM Claude², MS Serge², KK Alexis³, MT Hawkes^{1,4,5,6,7}¹Department of Pediatrics, University of Alberta, Edmonton, AB; ²Department of Medicine, Université Catholique du Gabon, Butembo, Democratic Republic of the Congo; ³Department of Ophthalmology, Université Catholique du Gabon, Butembo, Democratic Republic of the Congo; ⁴Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB; ⁵School of Public Health, University of Alberta, Edmonton, AB; ⁶Stollery Science Lab, University of Alberta, Edmonton, AB; ⁷Women and Children's Health Research Institute, University of Alberta, Edmonton, AB**SP39****Comprehensive genomic insight into Shiga-toxin producing *Escherichia coli* (STEC) to understand virulence and detect priority STEC serotypes**K Yousfi^{1,2}, RH Khan¹, C Landgraaf³, K Lanyon³, I Bernaquez¹, F Doualla-Bell¹, D Roy¹, S Bekal¹¹Laboratoire de Santé Publique du Québec, Ste Anne de Bellevue, QC; ²Université de Montréal, Montréal, QC; ³Division of Enteric Diseases, National Microbiology Laboratory, Winnipeg, MB**SP40****WITHDRAWN****SP41****Sapovirus molecular epidemiology in Canadian children: Insights from a 4-year province wide prospective study**X Ding¹, R Zhuo¹, L Jasper¹, J Xie², S Freedman², Y Wu¹, L Chui^{1,3}, B Lee¹, S Ali¹, X Pang^{1,3}¹University of Alberta, Edmonton, AB; ²Department of Pediatrics and Section of Pediatric Emergency Medicine, University of Calgary, Calgary, AB; ³Alberta Precision Laboratories, Edmonton, AB**SP42****Overuse of piperacillin-tazobactam in patients admitted to medicine wards**E MacAdam¹, P Gregory¹, P Bonnar^{1,2}¹Dalhousie University, Halifax, NS; ²Nova Scotia Health, Halifax, NS

SP43

Treatment of bloodstream infections caused by ceftriaxone-resistant *E. coli*, *P. mirabilis* and *Klebsiella* species: review of extended-spectrum beta-lactamase production and patient outcomes in a low prevalence setting
S Smith¹, H Al Sidairi^{2,3}, EK Reid⁴, C Smith⁵, G Patriquin⁵, P Bonnar^{3,4}, R Davidson⁵

¹IWK Health Centre, Halifax, NS; ²Laboratory Services Department, Ibri Referral Hospital, Ibri, Oman; ³Dalhousie University, Halifax, NS; ⁴Nova Scotia Health, Halifax, NS; ⁵Department of Pathology and Laboratory Medicine, Division of Microbiology, Nova Scotia Health, Halifax, NS

SP44

Prediction of cytomegalovirus antiviral resistance using next-generation sequencing in a clinical virology laboratory

S D Chorlton¹, G Ritchie^{1,2}, T Lawson^{1,2}, E McLachlan³, MG Romney^{1,2}, N Matic^{1,2}, CF Lowe^{1,2}

¹Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; ²Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, BC; ³National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

SP45

WITHDRAWN

SP46

Oral administration of defined microbial community (DCM-18) protects against *Clostridioides difficile* infection in mice

M Guzman¹, C Noordhof², SM He², E Allen-Vercoe³, D Hurlbut⁴, G B. Gloor⁵, SJ Vanner¹, EO Petrof¹, PM Sheth^{1,4,6}

¹Gastrointestinal Disease Research Unit (GIDRU), Department of Medicine, Queen's University, Kingston, ON; ²Gastrointestinal Disease Research Unit (GIDRU), Department of Medicine, Queen's University, Kingston, ON; ³Department of Molecular and Cellular Biology, University of Guelph, Guelph, ON; ⁴Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON; ⁵Department of Biochemistry, University of Western Ontario, London, ON; ⁶Division of Microbiology, Kingston Health Sciences Center, Kingston, ON

SP47

Quantifying the effect on case numbers of public health intervention in Canada's COVID-19 pandemic

MT Crocker¹, P Loudovski¹, W Wobeser^{1,2}, V Hoepfner³

¹Queen's University, Department of Public Health Sciences, Kingston, ON; ²Queen's University, Department of Biomedical and Molecular Sciences, Kingston, ON; ³University of Saskatchewan, Department of Medicine, Saskatoon, SK

SP48

Decreasing the incidence of external ventricular drain infections: Has standardizing insertion and management practices made a difference?

A Cvetkovic, A Shroff, C Main, D Mertz

McMaster University, Hamilton, ON

SP49

Creation of a cumulative antibiogram for local intensive care units reveals significant resistance

DB Duncan¹, D Yamamura^{1,2}, D Mertz^{1,2}, N Irfan^{1,2}

¹McMaster University, Hamilton, ON; ²Hamilton Health Sciences, Hamilton, ON

SP50

Evaluating correlates of viral shedding patterns in SARS-CoV-2 patients

KM Tozer^{1,2}, E Moslinger^{1,3}, J Lam⁴, A Khalil⁵, P Beddoe⁵, K Douchant^{1,2}, H Wong⁶, P Sheth^{1,2,3,6}

¹Gastrointestinal Disease Research Unit (GIDRU), Queen's University, Kingston, ON; ²Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON; ³Pathology and Molecular Medicine, Queen's University, Kingston, ON; ⁴Department of Medicine, Queen's University, Kingston, ON; ⁵Center for Advanced Computing, Queen's University, Kingston, ON; ⁶Division of Microbiology, Kingston Health Sciences Center, Kingston, ON

SP51

Fever and runny nose in a healthy adult patient: An interesting case of bacterial meningitis with normal CSF parameters

C Guenther¹, W Sligl², G Shumilak¹

¹University of Saskatchewan, Saskatoon, SK;

²University of Alberta, Edmonton, AB

SP52

Acceptability of self-collected samples for COVID-19 diagnosis in outpatients

E Finlayson-Trick¹, P Tilley^{1,2}, GN Al-Rawahi^{1,2}, JA Srigley^{1,2}, JM Pernica³, LMN Hoang^{1,4}, DM Goldfarb^{1,2}

¹University of British Columbia, Vancouver, BC; ²Division of Medical Microbiology, BC Children's Hospital & BC Women's Hospital & Health Centre, Vancouver, BC; ³Department of Pediatrics, McMaster University, Hamilton, ON; ⁴BC Centre for Disease Control, Vancouver, BC


AUTHOR INDEX

A

Abou-Mehrem, Ayman	P23	Borgia, Sergio	P30, P42
Adalbert, Jenna	SP27	Boucher, Valérie	E03
Adam, Heather	B01, P16, P18, P19, P22, SP34	Bourassa-Blanchette, Samuel	P25
Afra, Kevin	P14	Bowen, Raffick	P53
Ahmad, Muneera	P46	Bowes, Jennifer	C04, P74
Al Hashemi, Alaa	P46	Boyd, David	P03, P37, P56
Al Mutawa, Fatimah	P57	Bradley, John	C04
Al-Rawahi, Ghada	D02, P03, SP52	Brenes-Chacon, Helena	P74
Alemayheu, Gelila	C01	Brennan, Christopher	P02
Alexander, David	P05, P37	Bridger, Natalie	SP18
Alexis, Kahindo	SP38	Brooks, James	D02, P43, P60
Ali, Samina	SP41	Brown, Kevin	D01
Allen, Vanessa	P05, SP26	Brown, Kristen	SP04
Allen-Vercoe, Emma	SP11, SP46	Brundler, Marie-Anne	P23
Alloo, Javed	D01	Bryce, Elizabeth	B02
Alrohimi, Anas	SP05	Bugaj, Victoria	P40, SP29
Alsager, Khaled	D04, P64, SP13	Bullard, Jared	P74
Alvarado-Llano, Beatriz	P01, P50	Burak, Kelly	P21
Andrew, Melissa	P47	Burgess, Fred	P24
Anwer, Shaista	P78, P82	Burnes, Laura	A02, P34
Aquino, Ana	P75		
Ariano, Rob	P42		
Arumugam, Gnanalaxmi	P68, P69		
Avery, Brent	P05		
Azana, Robert	P54		

B

Baekyung Choi, Kelly	P43	Campbell-Scherer, Denise	P28, P29, P31, P32, P33, P52, P71
Bailey, Ashley-Nicole	P35		P13, P55
Bains, Serena	P20, P51	Campigotto, Aaron	P73
Balamohan, Archana	C04	Caron, Louise Josée	P83
Bancej, Christina	SP02	Carr, Georgia	P24, P58
Barakauskas, Vilte	E02	Carruthers, Erin	P05
Barker, Kevin	P13, SP12	Carson, Carolee	SP24
Barton, Michelle	C04, P74	Cashman, Neil	P20, P42
Baxi, Maulik	SP19	Cervera, Carlos	SP18
Baxter, Melanie	P30, P42, P48, SP34	Chafe, Roger	P24, P58, P65
Bayliss, Ann	P74	Chahil, Navdeep	P26
Beauchemin, Catherine	P06	Chan, April	P23
Beauchemin, Stéphanie	E03, P38, P73, P76	Chan, Elaine	P23
Beddoe, Paige	SP50	Chan, A. Uma	P28, P29, P31, P32, P34, P33, P52, P71
Bedi, Dylan	P49	Charles, Marthe	B02, E02, P68, P69, P70
Bekal, Sadjia	B04, P05, P56, SP39	Charlton, Carmen	P35, SP10
Benoit, Patrick	A04, P38	Chavda, Swati	SP21
Berenger, Byron	P23, P44	Checkley, Sylvia	SP01
Bergevin, Marco	P30, P76	Chen, Justin	A02, P20, P28, P29, P31, P32, P51, P52, P67, P71, SP05
Bernaquez, Isabelle	B04, P56, SP39	Chen, Tammy	P03
Bestman-Smith, Julie	E03	Chin, Ki Jinn	SP08
Bettinger, Julie	SP02	Choi, Kelly	D02
Bharat, Amrita	P05	Chorlton, Samuel	SP44
Bibby, Helen	SP04	Chow, Blanda	D02
Birnboim, H. Chaim	SP32	Chu, Ken	P24
Bitnun, Ari	P74	Chui, Linda	P05, SP41
Black, Emily	P15	Clancy, Cornelius	SP07
Blake, Molly	P37	Clark, Shawn	P39, P55, P75, SP36
Blancaflor, Rosemarie	P24	Claude, Kasereka	SP38
Blondel-Hill, Edith	P63	Claveau, David	P06
Bonnar, Paul	D03, SP42, SP43	Clifford-Rashotte, Matthew	P77
Bonneau, Eric	P38	Coburn, Bryan	SP20
Boodman, Carl	P37, SP25	Coleman, Brenda	P47
		Collet, Jun	D02
		Collins, Erin	SP32
		Comeau, Jeannette	D02, P15, P43
		Conly, John	P17, P23, P43, SP21
		Conrod, Davenna	P37



Constantinescu, Cora
 Cook, Darrel
 Cooke, Suzette
 Coombe, Michelle
 Coomes, Eric
 Cooper, Curtis
 Corriveau-Bourque, Catherine
 Coutlée, François
 Cowan, Tina
 Cox, Graham
 Crick, Katelynn P28, P29, P31, P32, P33, P52, P71
 Crocker, Matthew
 Cuarte, Audrey
 Cvetkovic, Anna

D04, P64, SP13
 E02
 P74
 SP09
 P47
 SP32
 SP23
 A04, P38
 P53
 P05
 P28, P29, P31, P32, P33, P52, P71
 SP47
 P03
 P59, SP48

El Bailey, Sameh
 El Tal, Tala
 El-Helou, Philippe
 Ellis, Chelsey
 Ellison, Jennifer
 Emberley, Julie
 Embil, John
 Englesakis, Marina
 Ernst, Jaclyn
 Etches, Nicholas
 Evans, David
 Evans, Gerald

P05
 P74
 P41, SP33
 P43
 P43
 SP18
 P37, P43
 SP08
 P07
 P17
 P12, P23
 D02, P01, P43, P50



D

Daignault, Danielle
 Daley, Peter
 Dalton-Kenny, Hedy
 Daneman, Nick
 Davidson, Ross
 Davies, H. Dele
 Davis, Ian
 DeAngelis, Carlo
 Deckert, Anne
 Delage, Gilles
 Dendukuri, Nandini
 Dersch-Mills, Deonne
 Desforges, Marc
 Devine, Dana
 Devlin, Megan
 Dewan, Tammie
 Dhaliwal, Inderdeep
 Dhaliwal, Suk
 Dhami, Rita
 Diaz Pallarez, Carolina
 Dibernardo, Antonia
 Diggle, Mathew
 Dillon, Jo-Anne
 Dimitrova, Kristina
 Ding, Xiaofeng
 Dingle, Tanis
 Dixit, Devika
 Dobrowolski, Peter
 Donovan, Catherine
 Doualla-Bell, Florence
 Doucette, Karen
 Douchant, Katya
 Dow, Gordon
 Downing, Mark
 Drebot, Michael
 Drews, Steven
 Du, Tim
 Duan, Jun
 Dube, Maxime
 Dubinski, William
 Dufresne, Simon Frédéric
 Dumaresq, Jeannot
 Duncan, D. Brody
 Dunn, Jessica
 Dupuis, Alan
 Dwillow, Rachel

P05
 SP14
 SP17
 A01, D01
 SP43
 C04
 D02, D03
 SP29
 P05
 P02, P04
 SP02
 P64, SP13
 P76
 P12
 P07
 P74
 P07
 P03
 P30, P42
 C03
 SP03
 P66
 C02
 SP03
 SP41
 B03, P67, SP31
 P17
 SP05
 SP17
 B04, E03, P56, P73, SP39
 P20, P51
 SP11, SP28, SP50
 P30, P42
 P26
 P12, P58, SP03
 E01, P02, P04, P12
 D02
 SP09, SP24
 P30, P42, P48
 P61
 P06
 P73
 SP49
 P23
 P12
 P74

F

Fafard, Judith
 Farghaly, Mai
 Farshait, Nataly
 Fearon, Margaret
 Feng, Lillian
 Filiatrault, Karine
 Finlayson-Trick, Emma
 Fjell, Chris
 Fong, Karen
 Fonseca, Kevin
 Foo, Cheryl
 Forbes, Jessica
 Fornika, Dan
 Foulds, Jessica
 Fournier, Stéphanie
 Freedman, Stephen
 Freire, Dolores
 Frenette, Charles
 Friedman, Steven
 Fritzler, Marvin
 Fryters, Susan P28, P29, P31, P32, P33, P52, P71
 Fung, Christopher



E03, P38, P73, P76
 SP01
 P13
 P02
 B03
 P38
 SP52
 P79, P81
 P20, P51
 P21, P23
 P74, SP18
 P39
 P54, P79, P81
 SP23
 P73
 SP41
 C04
 D02, P43
 E04
 P36
 P28, P29, P31, P32, P33, P52, P71
 P21



G

Gagnon, Simon
 Gamble, Gregory
 Gantt, Soren
 Garber, Gary
 Gaskin, Mark
 Gaudreau, Christiane
 Gaussen, Amaury
 German, Gregory
 Ghakis, Christiane
 Gharabaghi, Farhad
 Gibbs, Ebrima
 Gibson, Natalie
 Gilbert, Laura
 Gill, Peter
 Gillrie, Mark
 Girardin, Roxie
 Girouard, Gabriel
 Glassman, Heather
 Glier, Melissa
 Gloor, Gregory
 Gobeille Paré, Sarah
 Goldfarb, David
 Gonzalez, Marcela
 Gouliquer, Wendy
 Grandbois, Ella
 Grandjean-Lapierre, Simon
 Grant, Jennifer
 Gratrix, Jennifer


A04, P38
 P83
 SP24
 D01
 SP30
 B04
 P04
 P05, P43
 P45
 P55
 SP24
 P37
 SP17
 P74
 P36
 P12
 P48
 P34, SP05
 P72
 SP11, SP46
 E03
 SP52
 P45
 P83
 P65
 A04
 P70
 C03



E

Eksteen, Eduard
 El Ali, Radwan

P08
 P45



Gravel Tropper, Denise
 Gray, Jonathan
 Gregoire, Yves
 Gregory, Peter
 Gregson, Daniel
 Greydanus, Drew
 Grimshaw, Jeremy
 Guenther, Catherine
 Guinan, Kimberly
 Guirguis, Michael
 Guzman, Mabel

H

Haghighi Aski, Behzad
 Haider, Shariq
 Haldane, David
 Halperin, Scott
 Han, Guanghong
 Han, Ray
 Hansen, Bettina
 Hantid, Mellicie
 Hardy, Isabelle
 Harrigan, Richard
 Hasan, Mohammad
 Hassan, Kazi
 Hassan Khan, Rufaida
 Hawes, Gordon
 Hawkes, Michael
 Hayden, Althea
 Hazlett, Bryn
 He, Shu-Mei
 Hernandez-de Mezerville, Marcela
 Hickman, Rebecca
 Himsworth, Chelsea
 Hirtle-Lewis, Marika
 Hizon, Romeo
 Hoang, Holly
 Hoang, Linda

Hoepfner, Vernon
 Hogan, Catherine
 Hon, Benjamin
 Hookey, Sandy
 Hornby, Laura
 Hosseini, Sandra
 Hota, Susy
 Houston, Stanley
 Hsiao, William
 Hsu, Joanne
 Hu, Jia
 Huang, Chun Hong
 Hughes, Josie
 Hurlbut, David
 Hynes, Michael

I

Ioudovski, Paul
 Iranpour, Mahmood
 Irfan, Neal
 Irwin, Rebecca
 Isabel, Sandra
 Ismail, Samantha
 Ivankovich-Escoto, Gabriela
 Ivers, Noah

P60
 SP37
 P02
 SP35, SP42
 SP22
 P60
 D01
 SP51
 P06
 SP29
 SP11, SP46

J

Jacob-Wagner, Mariève
 Jadavji, Taj
 Jain, Devika
 Jamal, Alaina
 Jameison, Peter
 Jansen, Brad
 Janz, Loretta
 Jasper, Luong
 Jassem, Agatha
 Jenkinson, Richard
 Jetté, Angie
 Jia, Jian-Jun
 Jiao, Lei
 Johnson, Andrew
 Johnston, B. Lynn
 Johnstone, Jennie
 Joo, Pil

P74
 SP16
 P05
 SP02
 D02
 P72
 A01
 P68, P69

K

Kabbani, Dima
 Kamelian, Kimia
 Kandel, Christopher
 Kandel, Rita
 Kanji, Jamil
 Kariyawasam, Ruwandi
 Karlowsky, James
 Katz, Kevin
 Kaufmann, Daniel
 Kerkerian, Genevieve
 Keynan, Yoav
 Khalil, Amal
 Khan, Sarah
 Kibsey, Pamela
 King, Teagan
 Kishi, Leane
 Kisson, Melissa
 Knight, Braden
 Knoppers, Bartha
 Koh, Deborah
 Kosar, Justin
 Kowalewska-Grochowska, Kinga
 Krajden, Mel
 Krishnan, Anish
 Kuchinski, Kevin
 Kula, Brittany
 Kustra, Jesse
 Kwong, Jeffrey
 Kyada, Rutvin

E04, P75, P82, SP12
 SP28, SP46
 P74
 P54
 SP09
 SP18
 D02
 P28, P29, P31, P32, P52, P71
 B02, P03, P05, P54, P79,
 P81, SP52
 SP47
 P53
 P65
 SP17
 P04
 P14
 D02
 SP05
 SP09
 P70
 P21, P44
 P53
 P70
 SP46
 SP01

L

Labbé, Annie-Claude
 Lachaine, Jean
 Lagacé-Wiens, Philippe
 Laghdar, Zineb
 Lalancette, Linda
 Lam, Jasmine
 Landes, Megan
 Landgraaf, Chrystal
 Landry, Liette
 Lang, Amanda
 Langford, Bradley
 Langley, Joanne
 Langlois, Marc-André


SP47
 SP03
 P30, P42, P48, SP49
 P05
 P75
 P78
 P74
 D01

E03
 SP02
 SP36
 SP26
 P17
 B03
 P54
 SP41
 E02, SP24
 A01
 P38
 SP32
 SP17
 P36
 P43
 D02, P43
 A03

P20, P51
 P54
 A01, P47
 SP36
 P21, P35, P44
 P08, P66, SP31
 B01, P16, P18, P19, P22,
 P30, P37, P42, P48, SP34
 D02, P43, P47, SP26

A04
 P64
 P30
 SP50
 C04
 D02, P43
 P36, SP21
 B02, P68, P69
 P82
 P60
 P02
 SP33
 P30, P42
 A02, P08
 E02, P24, P58, SP24
 P64
 SP09
 P67, SP07, SP31
 P24
 P47
 SP27

E03, P38, P73, P76
 P06
 B01, P16, P18, P19, P22,
 P30, SP25, SP34
 P76
 P38
 SP50
 E04
 SP39
 P06
 C02, P21
 D01, P26
 D02
 SP32



Lanyon, Katrina
 Lau, Cecilia
 Lautermilch, Janell
 Lavallée, Christian
 Lavergne, Valéry
 Law, Sampson
 Lawrence, David
 Lawson, Tanya
 Laxer, Ron
 Le Saux, Nicole
 Le, Anthony
 Leal, Jeanine
 LeBlanc, Jason
 LeBlanc, Ryan
 Lee, Anna
 Lee, Bonita
 Lee, Claire
 Lee, Min-Kuang
 Lee, Tracy
 Lee, Yung
 Lefebvre, Marie-Astrid
 Leifso, Kirk
 Leis, Jerome
 Lemieux, Camille
 Lepe, Aurora
 Leung, Valerie
 Levett, Paul
 Lewin, Antoine
 Li, Fang Fang
 Li, Lisa
 Li, Xena
 Liljebjelke, Karen
 Lin, James
 Lindsay, Robbin
 Lishman, Hannah
 Liu, Aaron
 Liu, Qin
 Lo, Calvin
 Lo, Carson
 London, Sydney
 Longtin, Yves
 Loomer, Courtney
 Louie, Ted
 Lovinsky, Reena
 Lovrics, Olivia
 Lowe, Christopher
 Lutes, Sarah

M

MacAdam, Emily
 MacDonald, Clayton
 MacDonald, Kelly
 MacDonald, Kimberley
 MacFadden, Derek
 MacKinnon, Holly
 Mah, Jordan
 Main, Cheryl
 Mak, Annie
 Mak, Justin
 Makhoul, Natalie
 Mamun, Abdullah
 Man, Stephanie
 Manafif, Ali
 Mandell, Lionel
 Mangat, Rupinder
 Manguiat, Kathy



SP39
 P20, P51
 P74
 E03
 P77
 P21
 P58
 SP44
 P74
 C04, P10, P74, SP06
 P53
 SP22
 D03
 P51
 P30, P48
 D02, P43, SP41
 C01
 P65
 P54
 SP08
 C04, P43, P74
 P01, P50, P74
 D01, SP26
 E04
 C02
 D01
 E02, P24, P58
 P04
 SP24
 B02, P68, P69, P70
 P41, SP30
 SP01
 P12, P23
 P58, SP03
 P63
 SP24
 P75
 SP16
 P41, SP16
 SP14
 D02, P43
 SP03
 SP37
 P13
 SP08
 SP44
 P42
 SP35, SP42
 SP19
 P30
 P54, P79, P81
 SP20
 P15
 P36
 SP30, SP48
 E02, P24
 P53
 P14
 P63
 P72
 P74
 SP34
 SP37
 P12


Marra, Fawziah
 Marshall, Natalie
 Martin, Irene
 Martinez-Cajas, Jorge
 Masood, Shazia
 Mataseje, Laura
 Materniak, Stefanie
 Mathurin, Karine
 Matic, Nancy
 Matukas, Larissa
 Mazzulli, Tony
 McAlpine, Alastair
 McArthur, Andrew
 McCormack, James
 McDonald, Gerald
 McDonald, Michael
 McDonough, Kathleen
 McFarlane, Alexandra
 McGeer, Allison
 McKenna, Susan
 McLachlan, Elizabeth
 McLay, Jain
 McLennan, Meghan
 McManus, Janet
 McNamara, Isabella
 Meatherall, Bonnie
 Mehta, Kayur
 Mei He, Shu
 Melady, Don
 Melano, Roberto
 Mendoza, Emelissa
 Mertz, Dominik
 Mian, Qaasim
 Mincer, Jacqueline
 Minion, Jessica
 Mitchell, Robyn
 Mokashi, Vaibhav
 Morin, Estelle
 Morris, Andrew
 Morris, Chantal
 Morris, Shaun
 Morshed, Muhammad
 Moslinger, Emily
 Mourad, Omar
 Mponponsuo, Kwadwo
 Mrkobrada, Marko
 Mulvey, Michael
 Mushanski, Linda
 Myroniuk, Tyler

N

Najafi, Ramin
 Nateghian, Alireza
 Nazari, Mohammad
 Needle, Robert
 Neish, Drew
 Newhook, Leigh Anne
 Ng, Corrinne
 Ng, Herman
 Nguyen, M. Hong
 Nicholson, Michael
 Niruban, John
 Noordhof, Curtis

P27, P63, SP15
 P35, P66, SP19
 P13
 P01, P50
 E02
 P05, P37, SP26
 SP03
 P06
 SP44
 P13, P39
 E04, P75, P82, SP12, SP36
 C04
 SP20
 P27
 SP14
 P02
 P12
 P34
 A01, E04, P13, P43,
 P47, P82, SP26
 P01, P50
 SP44
 P61
 P24
 P12
 SP12
 P21
 SP02
 SP11
 P47
 SP20, SP26
 P12
 D02, P43, SP48, SP49
 SP38
 SP03
 C02, D02, P05, P43
 P43
 P59
 P08, SP23
 P27, SP15
 P61
 P74, SP02
 E02, P24, P58, P65, SP24
 SP28, SP50
 SP33
 P64, SP22
 P07
 P05, P37, SP26
 C02
 P28, P29, P31, P32, P33, P52, P71





O

O'Brien, Sheila
 O'Callaghan, Emma
 O'Connor, Deborah
 Olmstead, Andrea
 Ondro, Christine
 Oosthuizen, Madeline

E01, P02, P04
 P45
 P78
 E02
 P25
 SP05

Roberts, Ashley
 Robinson, Joan
 Rockl, Gary
 Romney, Marc
 Rooney, Ashley
 Rotstein, Coleman
 Roy, David
 Rudnick, Wallis
 Russell, Rodney
 Russell, Shannon

P74
 C04, P74
 P04
 SP44
 SP20
 P06, P48
 B04, P56, SP39
 P43
 SP17
 P54



P

Pambrun, Chantale
 Pang, Xiaoli
 Papenburg, Jesse
 Parmar, Nidhi
 Parmley, E. Jane
 Parotto, Matteo
 Passarelli, Patrick
 Patrick, David
 Patriquin, Glenn
 Pelude, Linda
 Penny, Ryan
 Peragine, Christine
 Peragine, Diana
 Perez-Patrigeon, Santiago
 Pernica, Jeffrey
 Petric, Martin
 Petrof, Elaine
 Petrovskaya, Tatiana
 Phillips, Nicholas
 Pidduck, Tamara
 Pieroni, Peter
 Pilon, Pierre
 Pinnell, Rhiannan
 Pinsky, Benjamin
 Plevneshi, Agron
 Point, Floriane
 Potter, Lisa
 Poutanen, Susan
 Povitz, Marcus
 Prystajacky, Natalie
 Purewal, Rupeena
 Purych, Dale

E01, P12
 SP41
 P74, SP02
 C02
 P05
 SP08
 C04
 P27, P63, SP15
 SP35, SP43
 D02, P43
 P03
 P40, P49, SP29, P80
 P80
 P01, P50
 C01, P41, SP52
 P58
 SP11, SP46
 P09
 P53
 P24
 P16, P18, P19, P22
 B04
 A03
 P53
 P13
 A04
 P02
 E04, P75, P78, P82, SP12
 SP15
 P54, P72, P79,
 P81, SP09, SP24
 C04, P74
 P03

S

Saatchi, Ariana
 Sadarangani, Manish
 Saeed, Sahar
 Sahoo, Malaya
 Salmon, Joanne
 Sandila, Navjot
 Sapir-Pichhadze, Ruth
 Savard, Patrice
 Savoie, Michel
 Saxinger, Lynora
 Sbihi, Hind
 Schindler, Richelle
 Schneeberger, Pierre
 Schwartz, Ilan
 Schwartz, Kevin
 Science, Michelle
 Sekirov, Inna
 Serge, Muyisa
 Shariff, Salimah
 Sheth, Prameet
 Shigayeva, Altynay
 Shing, Emily
 Shir-Mohammadi, Khaterreh
 Shroff, Anjali
 Shumilak, Geoffrey
 Shurgold, Jayson
 Sibai, Mamdouh
 Sidhu, Munjoat
 Sikora, Christopher
 Silva, Anada
 Silverman, Michael
 Simons, Janet
 Simor, Andrew
 Simpson, Christy
 Singh, Ameeta
 Singh, Mandeep
 Skar, Gwenn
 Skillen, Aaron
 Slayter, Kathryn
 Sligl, Wendy
 Smith, Carolyn
 Smith, Glenys
 Smith, Shawn
 Smith, Stephanie
 Smyczek, Petra
 Snedeker, Kate
 Somayaji, Ranjani
 Soraisham, Amuchou
 Soriano-Fallas, Alejandra
 Spackman, Eldon
 Speakman, Jane
 Spicer, Erin
 Srigley, Jocelyn
 St-Hilaire, Manon

P27, P63, SP15
 P74, SP02
 E01
 P53
 P25
 D03
 P04
 P56
 P42
 P28, P29, P31, P32, P33, P52, P71
 P54, P79, P81
 SP21
 SP20
 SP07, SP31
 D01
 D02, P15
 E02, P24, P58, SP24
 SP38
 SP15
 SP11, SP28, SP46, SP50
 P47
 D01
 SP32
 SP48
 SP51
 P60
 P53
 P68, P69, P70
 SP19
 D02
 D01, SP15
 E02
 P47
 P02
 C03
 SP08
 C04
 P83
 P15
 SP31, SP51
 SP43
 P60
 SP43
 A02, P20, P43, P51
 C03
 P17
 SP22
 P23
 P74
 SP22
 P68, P69
 P07
 C04, D02, P43, SP52
 E03



Q


Quach, Caroline


P43

R

Rajakumar, Irina
 Rajpurkar, Pranav
 Ramsay, Tim
 Ranger, Adriana
 Raphenya, Amogelang
 Rawlyk, Neil
 Reid, Emma
 Reid, Jennifer
 Reid-Smith, Richard
 Rennert-May, Elissa
 Restivo, Lea
 Rice, Chris
 Richardson, David
 Richardson, Susan
 Ritchie, Gordon

P25
 P53
 A03
 C04
 SP20
 SP01
 D03, SP43
 SP15
 P05
 SP22
 P74
 P21
 P13
 P55
 SP44





Stagg, Paula
 Stein, Markus
 Stewart, Jackson
 Stokes, William
 Strong, David
 Suddes, Michael
 Suh, Kathryn
 Sumner, Alison
 Swanston, Claire

T

Tadros, Manal
 Taljaard, Monica
 Tang, Patrick
 Tang, Vincent
 Tanunliong, Guadalein
 Tapalski, Dmitry
 Taylor, Robert
 Tchao, Christine
 Tessier, Jean-Francois
 Thampi, Nisha
 Thompson, L Alexa
 Tian, Chenchen
 Tijet, Nathalie
 Tilley, Peter
 Timberlake, Kathryn
 Timoskova, Elena
 Tomlinson, George
 Tourangeau, Francine
 Tozer, Kyla
 Trajtman, Adriana
 Tremblay, Cécile
 Tremblay, Sonia
 Tsang, Frankie
 Tsang, Melanie
 Tse-Chang, Alena
 Tsekrekos, Stephen
 Turenne, Christine
 Turnbull, LeeAnn
 Tyrrell, Gregory
 Tyson, John



U

Ugarte Torres, Alejandra
 Ulloa-Gutierrez, Rolando
 Unger, Sharon

V

Vaisman, Alon
 Vallières, Emilie
 Vancol-Fable, Fabiola
 Vanner, Stephen
 Varshney, Karan
 Vaudry, Wendy
 Vayalumkal, Joseph
 Vegdani, Tasnim
 Velapatino, Billie
 Vermeiren, Christie
 Viel-Thériault, Isabelle

D02, P43
 B01, P16, P18, P19, P22
 P20, P51
 P44
 C03
 P17
 D02, P43
 SP16
 B02


P55
 D01
 P46
 B02
 SP24
 P09, P11
 SP34
 P72
 P42
 D02, P43
 P35, SP10
 SP08
 SP26
 P03, SP52
 P15
 P11
 SP08
 P73
 SP28, SP50
 P74
 A04
 P38
 P72
 P26
 P28, P32, P33
 P17
 B03
 SP19
 P54

B01, P16, P18, P19, P22, P37

W

Wada, Ray
 Walker, Sandra
 Walkty, Andrew
 Wang, Bing
 Wang, Peizhong
 Wanlin, Tasker
 Ward, Sheila
 Weaver, Victoria
 Webster, Duncan
 Weiss, Amanda
 Weiss, Matthew
 Welbourne, David
 Widdifield, Jessica
 Widla, Joanna
 Williams, David
 Williams, Victoria
 Willis, Lori
 Wilson, Evan
 Winkelaar, Gerrit
 Wobeser, Wendy
 Wong, Alice
 Wong, Han
 Wong, Henry
 Wong, Jacqueline
 Wong, Maggie
 Wong, Simon
 Wong, Titus
 Woo, Allan
 Wood, Heidi
 Woodward, Kevin
 Wu, Ge
 Wu, Julie
 Wu, Manhong
 Wu, Ying
 Wuerz, Terence

P24
 P40, P49
 B01, P16, P18, P19, P22,
 P30, P42, P48, SP34
 B02
 SP17
 C02
 P02
 P77
 SP03
 P17
 P04
 P83
 A01
 P61
 P28, P29, P31, P32, P33, P52, P71
 SP26
 P24
 P01, P50
 P31
 SP47
 D02, P43
 A03
 SP28, SP50
 P74
 P14
 P56
 P77
 P21
 P12, P58, SP03
 P59
 SP36
 D01
 P53
 SP41
 P16, SP25



X

Xie, Jianling
 Xie, Max

SP41
 P63

Y


Yamamura, Deborah
 Yau, Yvonne
 Yee, Noelle
 Yeh, E.
 Yeung, Eugene
 Yeung, Roseanne
 Yipp, Bryan
 Yock-Corrales, Adriana
 Yousfi, Khadidja
 Yu, Yang

SP49
 P55, P78
 SP20
 P74
 P10, SP06
 P28, P29, P32, P31, P33, P52, P71
 P36
 P74
 P56, SP39
 SP17

Z

Zahariadis, George
 Zelyas, Nathan
 Zhanel, George
 Zhuo, Ran
 Zittermann, Sandra
 Zvonar, Rosemary

P05, SP17
 P44, P66
 P30, P42, P48, SP34
 SP41
 SP26
 P42



CONFLICT OF INTEREST DECLARATIONS

Full name	Role(s)	Disclosure
Alemayheu, Gelila	Oral Abstract Presenter	No Conflict Declared
Alsager, Khaled	Oral Abstract Presenter	No Conflict Declared
Behr, Marcel	Speaker	No Conflict Declared
Benoit, Patrick	Oral Abstract Presenter	Grant: Roche
Bernaquez, Isabelle	Oral Abstract Presenter	No Conflict Declared
Brabant-Kirwan, Danielle	Scientific Planning Committee	No Conflict Declared
Burnes, Laura	Oral Abstract Presenter	No Conflict Declared
Charles, Marthe	Scientific Planning Committee	Honoraria: Merck (MA-CanadianSMARTExpertInputForum2020)
Charlton, Carmen	Central Planning Committee	Grant: Merck (Investigator Initiated)
Chagla, Zain	Co-developed presentation speaker	Advisory Board: GSK, Merck; Grant: Roche
Connors, William	Scientific Planning Committee	No Conflict Declared
Di Quinzio, Melanie	Scientific Planning Committee	No Conflict Declared
Dingle, Tanis	Central Planning Committee	Grant: BioMerieux, Amplyx, Avir Pharma, F2G and JMI laboratories (Investigator)
Du, Tim	Oral Abstract Presenter	No Conflict Declared
Fattouh, Ramzi	Scientific Planning Committee	No Conflict Declared
Ferris, Dwight	Sponsorship Committee	Advisory Board: Abbvie and Gilead; Honoraria: Gilead, Merck, Abbvie, GSK, ViiV and Verity
Forgie, Sarah	Central Planning Committee	No Conflict Declared
Fuller, Jeff	Central Planning Committee, Sponsorship Committee	No Conflict Declared
Goldfarb, David	Speaker	Grant: BioMerieux, Perkin Elmer (Investigator)
Haider, Shariq	Central Planning Committee, Sponsorship Committee	Advisory Board: Merck, Pfizer, Takeda; Grants: AVIR Pharma, Verity Pharma, Merck, Takeda, Cidara Pharma
Hatchette, Todd	Central Planning Committee	Grant: GSK and Pizer (Investigator initiated for Severe Outcome Surveillance Network (SOS) of influenza and CAP in hospitalized adults (Shelly McNeil PI))
Hogan, Catherine	Scientific Planning Committee	Honorarira: Inflammatrix
Jassem, Agatha	Central Planning Committee	No Conflict Declared

Full name	Role(s)	Disclosure
Johnstone, Jennie	Scientific Planning Committee, Speaker	No Conflict Declared
Kandel, Christopher	Oral Abstract Presenter	No Conflict Declared
Khan, Farhan	Scientific Planning Committee	No Conflict Declared
Khan, Kamran	Speaker	Founder/CEO: BlueDot
Kitai, Ian	Speaker	No Conflict Declared
Kozak, Robert	Central Planning Committee, Scientific Planning Committee, Speaker	Honorario: Chinese American Medical Society; Grant: GUARDRx, CANhealth
Krajden, Mel	Speaker	Grant: Roche, Hologic, Siemens and DiSorin
Labbé, Annie-Claude	Oral Abstract Presenter	Advisory Board: Merck, Pfizer
Lagacé-Wiens, Philippe	Scientific Planning Committee	No Conflict Declared
Langley, Joanne	Speaker	Grant: Pfizer, Merck, GSK, Medicago, IMV, VBI, Vido-Intervac, Sanofi-Pasteur, Entos, Precision Nanosystems and Symvivo
Lavallée, Christian	Central Planning Committee	Advisory Board: Merck; Grant: Merck (Co-investigator)
Li, Lisa	Oral Abstract Presenter	No Conflict Declared
Lowe, Christopher	Central Planning Committee	Grant: Genome BC (Co-PI on the development of SARS-CoV-2 diagnostics(COV-115)); Merck (Investigator on development of a next-generation sequencing assay for CMV resistance); Canadian Liver Foundation (Co-I for assessing the prevalence of hepatitis B carriers in Greater Vancouver)
Macdonald, Noni	Speaker	No Conflict Declared
Mak, Annie	Oral Abstract Presenter	No Conflict Declared
Malejczyk, Kathy	Scientific Planning Committee	No Conflict Declared
McAlpine, Alastair	Oral Abstract Presenter	No Conflict Declared
McDonald, Emily	Co-developed presentation speaker	No Conflict Declared
McMullin, Kathleen	Speaker	No Conflict Declared
Menzies, Dick	Speaker	No Conflict Declared
Mertz, Dominik	Speaker	No Conflict Declared
Miller, Matthew	Co-developed presentation speaker	Advisory Board: Seqirus; Grant: Medicago
Murthy, Srinivas	Speaker	No Conflict Declared
Nagai, Esther	Scientific Planning Committee	No Conflict Declared
Naus, Monika	Speaker	No Conflict Declared
Parmar, Nidhi	Oral Abstract Presenter	No Conflict Declared

Full name	Role(s)	Disclosure
Patel, Samir	Scientific Planning Committee	No Conflict Declared
Patrick, David	Scientific Planning Committee	No Conflict Declared
Patriquin, Glenn	Scientific Planning Committee, Speaker	No Conflict Declared
Pieroni, Peter	Scientific Planning Committee	No Conflict Declared
Pinnell, Rhannan	Oral Abstract Presenter	No Conflict Declared
Poutanen, Susan	Central Planning Committee, Scientific Planning Committee	Honoraria: Merck; Advisory Board: Verity, Paladin Labs; Research Support: bioMerieux
Press, Natasha	Speaker	No Conflict Declared
Reid, Emma	Oral Abstract Presenter	No Conflict Declared
Robinson, Joan	Speaker	No Conflict Declared
Rubin, Earl	Scientific Planning Committee	Honoraria: GSK; Advisory Board: GSK, Pfizer, Novartis; Grants: MSD, Pfizer (Vaccine Trials)
Russell, Valentina	Scientific Planning Committee	No Conflict Declared
Saeed, Sahar	Oral Abstract Presenter	No Conflict Declared
Salmon, Joanne	Scientific Planning Committee	No Conflict Declared
Saxinger, Lynora	Co-developed presentation speaker	No Conflict Declared
Schreiber, Yoko	Scientific Planning Committee	No Conflict Declared
Schwartz, Kevin	Oral Abstract Presenter	No Conflict Declared
Sheth, Prameet	Scientific Planning Committee	No Conflict Declared
Simor, Andrew	Central Planning Committee	No Conflict Declared
Smith, Stephanie	Speaker	No Conflict Declared
Stephen, Craig	Speaker	No Conflict Declared
Strathdee, Steffanie	Speaker	Stocks: Adaptive Phage Therapeutics
Tran, Vanessa	Scientific Planning Committee	No Conflict Declared
Turenne, Christine	Central Planning Committee, Scientific Planning Committee	No Conflict Declared
Ugarte Torres, Alejandra	Oral Abstract Presenter	No Conflict Declared
Vinh, Donald	Sponsorship Committee	Honoraria: CSL Behring Canada (Speaker. Site investigator for clinical trial. Principal investigator for clinical trial); Advisory Board: CSL Behring Canada, Avir Pharma, Merck Canada and Takeda; Grant: CSL Behring Canada, Cidara Therapeutics, Janssen Pharmaceutical
Weaver, Victoria	Members in Training Committee, Oral Abstract Presenter	No Conflict Declared
Wong, Titus	Speaker, Sponsorship Committee	No Conflict Declared
Yamamura, Deborah	Central Planning Committee	No Conflict Declared

INDUSTRY CO-DEVELOPED PRESENTATIONS

These educational events are Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. These programs have been co-developed with AMMI Canada and are planned to achieve scientific integrity, objectivity and balance.

Date: Monday, April 26
Time: 10:15 – 11:15 EDT
Auditorium: Co-developed Presentations

The influenza vaccine (r)evolution

Moderator: Philippe Lagacé-Wiens (Winnipeg, MB)

Speaker: Matthew Miller (Hamilton, ON)

By the end of the session the participants will be able to:

- Outline the main factors that impact annual influenza vaccine effectiveness
- Identify limitations in the use of randomized controlled trials to compare seasonal influenza vaccine efficacy
- Appreciate the need for real-world data related to influenza vaccines

Date: Wednesday, April 28
Time: 11:00 – 12:00 EDT
Auditorium: Co-developed Presentations

Strategic Deployment of COVID-19 Treatment Options: Who, What, Where and How?

Moderators: William Connors (Vancouver, BC)
 Marthe Charles (Vancouver, BC)

Speakers: Lynora Saxinger (Edmonton, AB)
 Emily McDonald (Montreal, QC)
 Zain Chagla (Hamilton, ON)

By the end of the session the participants will be able to:



- Review risk factors for development and progression of COVID-19 and the impact of vaccination
- Discuss the use of therapeutics in outpatients with COVID-19, including how to deploy them and to whom
- Discuss the strategic use of therapeutics in inpatients with COVID-19




While CFID members will not have the opportunity to come together in person at AMMI Canada – CACMID Annual Conference 2021, we are moving ahead with a safe and morale boosting 2021 Bug Run. We encourage all CFID members to undertake their own 5K run/walk from **April 1st to April 30th** (while incorporating proper public health practices).

Virtual participants are encouraged to take a “selfie” of themselves and submit their photos (Create a “Submit Photo” Button that links: cfid@researchid.com) Participants will be eligible for prizes and photos will be collected so that a final montage of virtual walkers and runners can be posted on the CFID website. You are also encouraged to donate to the Bug Run (Create a “Donate” Button that links: <https://www.researchid.com/support-us/donate-now/>.)

Our mandate – to improve the health of Canadians and people worldwide through the support of research and dissemination of knowledge pertaining to the prevention, diagnosis, control and treatment of infectious disease – has never been more relevant.



ANNUAL CONFERENCE
CONFÉRENCE ANNUELLE
AMMI Canada - CACMID

UNACCREDITED PRESENTATIONS

UNACCREDITED LEARNING ACTIVITIES



The Year in Clinical Virology – SARS-CoV-2 and Beyond

Date: Monday, April 26
Time: 15:30 – 16:00 EDT
Location: Main Auditorium

Presented by PASCV Member, Dr. Benjamin Pinsky, this session will review the most impactful publications in clinical virology over the past year.


By the end of this session, participants should be able to:

- Discuss the latest developments in diagnostic virology

Speaker:

Benjamin Pinsky, MD, PhD
Medical Director, Clinical Virology Laboratory
Stanford Health Care and Stanford Children's Health
Medical Co-director, Point of Care Testing
Medical Director, Esoteric (send-out) Testing

Visit the PASCV booth in the Exhibit Hall for more details



COVID-19 and Long-Term Care – What does the future hold?

Date: Monday, April 26
Time: 16:00 – 16:30 EDT
Location: Unaccredited Presentation Auditorium

Pre-registration required, maximum of 50 people

This talk will review the challenges of COVID-19 outbreaks in long term care and the progress in mitigation made prior to and with vaccines and discuss what possible outcomes lie ahead for the relationship between COVID-19 and long-term care.

By the end of this session, participants should be able to:

- To review the history of COVID-19 in long term care in the pandemic today

- To describe the immunogenicity and effectiveness of mRNA vaccines in this population
- To discuss predictions for the 2020/21 winter


Speaker:

Allison McGeer, MD, FRCPC
Microbiologist, Infectious Disease Consultant
Department of Microbiology
Mount Sinai Hospital

Moderator:

Marlene Jantzi, RN, MPH, BScN, CIC
Liaison Section Chief, COVID-19 Response
Program Manager, Control of Infectious Diseases
Wellington-Dufferin-Guelph Public Health

Visit the Pfizer booth in the Exhibit Hall for more details



UNACCREDITED LEARNING ACTIVITIES

LIAISON XL® SARS-CoV-2 Serological Testing

Date: Monday, April 26
Time: 16:30 – 16:45 EDT
Location: Unaccredited Presentation Auditorium

With over 50 years of experience, DiaSorin is a global leader in the laboratory diagnostics market, specializing in the immunodiagnostics and the molecular diagnostics segments. DiaSorin is continuing to aid in the COVID-19 pandemic response through innovative high-throughput and near patient testing solutions. The presentation will focus on a novel SARS-CoV-2 IgG assay that utilizes the full-length trimeric spike protein to detect immune response in a highly sensitive and specific manner.

Speaker:
 Jeff Kormos, MSc., MBA
 Corporate Vice President
 DiaSorin

DiaSorin

Visit the DiaSorin booth in the Exhibit Hall following the presentation for a question and answer session and for more information on DiaSorin



HOLOGIC® The Science of Sure

OPENING UP THE WORLD OF MOLECULAR DIAGNOSTICS: More than STIs beyond the pandemic

Date: Tuesday, April 27
Time: 10:30 – 11:30 EDT
Location: Unaccredited Presentation Auditorium

Pre-registration required, maximum of 100 people

Technology and instrumentation capabilities in the field of molecular diagnostics has reached most Canadian labs through the course of 2020. Hologic will provide an overview of their Panther platform, walk you through the journey of STI testing up to emerging pathogens and open to possibilities to reach automation and consolidation beyond IVD testing through LDTs.


By the end of this session, participants should be able to:

- Get familiar with the most recent innovations in the field of molecular diagnostics instrumentation technology

- Understand there are overlapping symptoms of vaginal pathogens
- Learn about the possibilities beyond testing for STIs through open access without compromising automation and consolidation

Speakers:
 Tyler Park
 Director, Laboratory Marketing
 Damon Getman
 Director Scientific Affairs
 Elenyah Klein
 Senior Marketing Manager, Instrumentation

Visit the Hologic Inc. booth in the Exhibit Hall for more details



UNACCREDITED LEARNING ACTIVITIES



Date: Tuesday, April 27
Time: 16:00 – 17:00 EDT
Location: Unaccredited Presentation Auditorium

Pre-registration required, maximum of 100 people


By the end of this session, participants should be able to:

- Review ongoing clinical burden and latest epidemiologic (serotype distribution) data for invasive pneumococcal disease in Canada: highlight national and regional trends
- Delineate key serotypes (both vaccine and non-vaccine types) of ongoing concern in context of existing pneumococcal immunization programs

Evolving epidemiology and serotype distribution of invasive pneumococcal disease: what's driving the ongoing clinical burden in Canada?

Speaker:
 Angel Chu, MD, FRCPC, SPEC, COMP
 Assistant Professor
 Infectious Disease
 University of Calgary

Visit the Merck Canada booth in the Exhibit Hall for more details



AVIR Adding insult to injury: fungal infections complicating COVID-19

Date: Wednesday, April 28
Time: 16:00 – 16:30 EDT
Location: Unaccredited Presentation Auditorium


Pre-registration required, maximum of 25 people

By the end of this session, participants should be able to:

- Review of COVID-Associated Pulmonary Aspergillosis' (CAPA) pathophysiology and epidemiology
- Describe an algorithm to its diagnosis and management
- Provide an overview of interesting real-life cases

Speaker:
 Ilan Schwartz, MD PhD
 Assistant Professor
 University of Alberta

Visit the AVIR Canada booth in the Exhibit Hall for more details



UNACCREDITED LEARNING ACTIVITIES



The Antimicrobial Resistance Landscape in Canada and how we are tackling the problem

Date: Thursday, April 29
Time: 10:15 – 11:15 EDT
Location: Unaccredited Presentation Auditorium

Speakers:
 Gerry Wright PhD
 Director, Professor
 Michael G. DeGroot Institute for Infectious Disease Research
 Department of Biochemistry and Biomedical Sciences
 Canada Research Chair in Antibiotic Biochemistry, McMaster University



This event will review Antimicrobial trends globally and in Canada, and describe the existing surveillance programmes, and opportunities to enhance surveillance. Furthermore, it will discuss the Pan Canadian Action Plan and barriers/enablers to roll it out and foster a One Health approach in Canada and globally.

Susan Poutanen MD, MPH, FRCPC
 Associate Professor
 Department of Laboratory Medicine & Pathobiology
 Medical Microbiologist, University Health Network/
 Sinai Health Department of Microbiology
 Infectious Disease Physician, University Health Network and Mount Sinai Hospital


By the end of this session, participants should be able to:

- Review AMR trends globally and nationally.
- Describe existing surveillance programmes and opportunities for enhanced surveillance
- Discuss the Pan Canadian Action Plan
- Discuss barriers and enablers to rolling out the action plan and fostering a One Health approach in Canada and globally.

Visit the Merck Canada booth in the Exhibit Hall for more details



UNACCREDITED LEARNING ACTIVITIES



SARS-CoV-2 Variants of Concern: What's the Concern?

Date: Friday, April 30
Time: 11:00 – 12:00 EDT
Location: Unaccredited Presentation
Auditorium

With the ongoing COVID-19 pandemic, challenges continually emerge for healthcare facilities. We will discuss the changing epidemiology of Variants of Concern (VoC) and the challenges to the laboratory response to the detection of these variants.

By the end of this session, participants should be able to:

- Describe the emerging epidemiology of SARS-CoV-2 variants of concern
- Outline laboratory approaches to the identification of SARS-CoV-2 variants of concern
- Discuss ongoing challenges the laboratory faces in response to SARS-CoV-2 variants of concern

Speakers:

Christopher Lowe MSc, MD, FRCPC
Clinical Professor
UBC Dept. of Pathology & Laboratory Medicine
Medical Microbiologist, Providence Health

Nancy Matic MD
Clinical Assistant Professor,
UBC Dept. of Pathology & Laboratory Medicine
Medical Microbiologist, Providence Health

Moderator:

Caroline Vincent
Medical Liaison
Cardiology, Prenatal Care and Infectious Diseases

**Visit the Roche Diagnostics booth
in the Exhibit Hall for more details**





EXHIBIT HALL



The annual conference has received tremendous support from our industry partners - be sure to visit the Exhibit Hall.


You can access the booths, virtually on the platform by clicking on the company name found in the Exhibitors Index or by scrolling through the 3D exhibit hall.

Exhibit Hours

The Exhibit Hall will be available on demand during the conference and for one month post event.

Dedicated times have been scheduled for booth representatives to be available for live 1:1 chats or via text chat on the platform.

Monday, April 26	16:00 - 18:00 EDT
Wednesday, April 28	15:45 - 18:00 EDT
Thursday, April 29	13:30 - 15:00 EDT
Friday, April 30	10:00 - 12:00 EDT




EXHIBITORS INDEX

Abbott Laboratories
 Association of Medical Microbiology and Infectious Disease Canada
 AVIR Pharma Inc.
 Becton Dickinson Canada Inc.
 Bio-Rad Laboratories
 BioMérieux Canada, Inc.
 Canadian Association of Clinical Microbiology and Infectious Diseases
 Canadian Foundation for Infectious Diseases
 DiaSorin Canada
 Gilead Sciences Canada
 Hologic Canada ULC
 Horizon Health Network
 Infectious Disease Society of America and IDWeek

Innovatek Medical
 Inter Medico
 Merck Canada Inc
 Micronostyx
 Nosotech
 Pan American Society for Clinical Virology
 Pfizer Canada Inc.
 Pro-Lab Diagnostics Inc.
 Public Health Physicians of Canada
 Quidel Canada
 Randox Laboratories
 Roche Diagnostics
 Seegene Canada Inc.
 Seqirus Canada
 Somagen Diagnostics Inc.
 Thermo Fisher Scientific – Microbiology
 Verity


SPONSORS



MERCK



GILEAD



GENERAL INFORMATION

Conference Secretariat

192 Bank Street
Ottawa, ON K2P 1W8, Canada
Tel.: (613) 260-3233 ext. 105
Toll-free: 1 (888) 467-1215 ext. 105
meetings@ammi.ca

www.ammi.ca
www.cacmid.ca

Registration Information

Unconventional Planning

32 Colonnade Road, Unit 100
Ottawa, ON K2E 7J6, Canada

Tel.: (613) 721-7061
Toll-free: 1 (888) 625-8455
registration@unconventionalplanning.com